

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/035712 A2

- (51) International Patent Classification⁷: C12N (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/US2004/023548
- (22) International Filing Date: 21 July 2004 (21.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/488,942 21 July 2003 (21.07.2003) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for all designated States except US): UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; 308 Bynum Hall, Campus Box 4105, Chapel Hill, North Carolina 27599-4105 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BARIC, Ralph S. [US/US]; 2600 Northstream Court, Haw River, North Carolina 27258-9529 (US). YOUNT, Boyd [US/US]; 1002 Scotsburg Trail, Hillsborough, North Carolina 27278 (US). CURTIS, Kristopher M. [US/US]; 102 Water Land Court, Frederick, Maryland 21702 (US).
- (74) Agent: MYERS BIGEL SIBLEY & SAJOVEC, P.A.; P.O. Box 37428, Raleigh, North Carolina 27627 (US).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 2005/035712 A2

(54) Title: METHODS AND COMPOSITIONS FOR INFECTIOUS CDNA OF SARS CORONAVIRUS

(57) Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.

**METHODS AND COMPOSITIONS FOR INFECTIOUS cDNA
OF SARS CORONAVIRUS**

STATEMENT OF PRIORITY

5

This application claims the benefit, under 35 U.S.C. § 119(e), of U.S. provisional application number 60/488,942, filed July 21, 2003, the entire contents of which are incorporated by reference herein.

10

STATEMENT OF FEDERAL SUPPORT

This invention was supported by government funding under grant numbers A123946 and GM 63228 from the National Institute of Health, Allergy and Infectious Diseases. The United States Government has certain rights to this invention.

15

FIELD OF THE INVENTION

The present invention relates to compositions of infectious cDNA of the severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, SARS coronavirus replicon particles, methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.

20

BACKGROUND OF THE INVENTION

Severe acute respiratory syndrome is a life-threatening respiratory disease that probably originated in Guangdong Province, China in the fall of 2002 [1, 2]. The agent responsible for the disease spread rapidly [3, 4]. A novel coronavirus (SARS-CoV), isolated from febrile and dying patients, is the etiologic agent responsible for the disease [5-8]. SARS-CoV infection is associated with overall case fatality rates thought to approach ~14-15%, with selected populations being at increased risk (>50% in the elderly). SARS-CoV has infected over 8,000 individuals worldwide and caused over 800 deaths, before aggressive infection control measures successfully contained the scope of the outbreak. Despite intensive efforts, no effective antiviral treatments against SARS have been described.

25

Coronaviruses, members of the order Nidovirus, contain the largest single-stranded, positive-polarity RNA genome in nature and are divided into three main

30

serogroups; group I: transmissible gastroenteritis virus (TGEV) and human coronavirus 229E (HCV-229E), group II: mouse hepatitis virus (MHV) and bovine coronavirus (BoCV), and group III: infectious bronchitis virus (IBV). Sequence analyses suggest that SARS-CoV represents the prototype strain of group IV [6, 8-10]. The SARS-CoV genomic RNA is ~29,700 base pairs in length and has several large open reading frames (ORFs) encoded in subgenomic and full-length mRNAs [8-10]. The subgenomic mRNAs are arranged in the form of a nested set from the 3' proximal end, and leader RNA sequences, encoded at the 5' end of the genome, are joined to body sequences at a highly conserved consensus sequence (CS) located just upstream of each of the ORFs. The exact SARS CS sequence has been reported as either CUAAAC or AAACGAAC by different laboratories [8, 9]. The SARS-CoV genome length RNA is likely packaged by a 50-kDa-nucleocapsid protein (N) [8]. As with other coronaviruses, the virion contains several viral structural proteins including the ~140 kDa spike glycoprotein (S), a 23 kDa membrane glycoprotein (M) and a ~10 kDa protein (E).

The coronavirus gene 1, or replicase gene, comprises two-thirds of the genome. MHV contains two overlapping open reading frames, ORF1a and ORF1b, which are connected by a ribosomal frameshift structure. In MHV, three proteinases, papain-like proteinases 1 and 2 (PLP-1, PLP-2) [11-13] and 3C-like proteinase (3CLpro) [14], are expressed as part of the replicase gene polyprotein and mediate cleavage of the polyproteins into at least 15 mature proteins. Continuous protein processing is crucial for ongoing virus transcription so MHV replication is sensitive to protease inhibitors that prevent replicase processing [11]. Additional functions have been predicted for proteins processed from the replicase polyprotein, including an RNA-dependent RNA polymerase (pol), an RNA helicase (hel) and a capping enzymatic activity [6, 15, 16]. The SARS virus replicase gene is similarly organized except that the SARS virus replicase has been predicted to encode only the PLP-2 equivalent and the 3CLpro proteases [6, 7].

The present invention provides a full length cDNA of the SARS coronavirus, from which transcripts are produced that replicate and/or are infectious *in vitro* or *in vivo*, multiplication-defective replicon vector particles produced from the cDNA and

methods of making and using these compositions as immunogens, vaccines and/or nucleic acid delivery vectors.

SUMMARY OF THE INVENTION

5 The present invention provides a cDNA of the SARS coronavirus, from which transcripts are produced that replicate and/or are infectious *in vitro* or *in vivo*. Two examples of a nucleic acid sequence encoding a cDNA of this invention are provided in the attached Sequence Listing as SEQ ID NO:1 and SEQ ID NO:3. As this
10 invention encompasses all such cDNAs of all SARS coronavirus isolates, in one embodiment, the present invention provides an isolated nucleic acid comprising, consisting of and/or consisting essentially of, a nucleotide sequence selected from the group consisting of: a) SEQ ID NO:1 or SEQ ID NO:3 or a fragment of at least 25 contiguous nucleotides of SEQ ID NO:1 or SEQ ID NO:3; b) a nucleotide sequence
15 that is functionally equivalent to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3 but comprises different codons encoding the same amino acid sequences; c) a nucleotide sequence having at least 70% homology to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3; d) a nucleotide sequence having at least 95% homology to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3; e) a nucleotide sequence
20 that hybridizes to the complement of SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions; and f) a nucleotide sequence having complete complementarity to the nucleotide sequence of (a) – (e) above.

 Further provided herein is a cDNA of a SARS coronavirus, wherein all or part
25 of a nucleotide sequence of the cDNA is deleted and wherein the nucleotide sequence is selected from the group consisting of a nucleotide sequence encoding ORF1, ORF2, ORF3a, ORF3b, ORF4, ORF5, ORF6, ORF7a/b, ORF8a/b, ORF9a, ORF9b and any other ORF of a SARS coronavirus now known or later identified, and any combination thereof.

30

 The present invention further provides a cDNA of a SARS coronavirus, comprising a mutation in a nucleotide sequence of the cDNA, selected from the group consisting of a nucleotide sequence encoding ORF1, ORF2, ORF3a, ORF3b, ORF4, ORF5, ORF6, ORF7a/b, ORF8a/b, ORF9a, ORF9b, ORF 10, ORF 13, ORF 14, any

other ORF of a SARS coronavirus now known or later identified, and any combination thereof, wherein the mutation results in a nonfunctional gene product.

In an additional embodiment, the present invention provides a cDNA of a SARS coronavirus, wherein the order of nucleotide sequences of the cDNA encoding replicase, accessory ORFs and/or structural proteins S, E, M and N is rearranged in comparison to the order in wild type SARS coronavirus.

Additionally provided herein is a cDNA of a SARS coronavirus, wherein one or more of the nucleotide sequences encoding replicase, accessory ORFs and/or structural proteins S, E, M and N is present two or more times.

The present invention further provides a cDNA of a SARS coronavirus, comprising an attenuating mutation in a consensus sequence of the nucleotide sequence of the cDNA, selected from the group consisting of a leader consensus sequence, an S (ORF2) consensus sequence, an ORF3a consensus sequence, an E consensus sequence, an M consensus sequence, an ORF6 consensus sequence, an ORF7 consensus sequence, an ORF8 consensus sequence, an N consensus sequence, and any combination thereof.

In one embodiment provided herein, the present invention provides a cDNA of a SARS coronavirus comprising a 29 bp insertion in ORF8a/b.

Also provided herein is a cDNA of a SARS coronavirus, wherein all or part of a nucleotide sequence of the cDNA is deleted and wherein the nucleotide sequence is selected from the group consisting of a nucleotide sequence encoding ORF1, ORF2, ORF3a, ORF3b, ORF4, ORF5, ORF6, ORF7a/b, ORF8a/b, ORF9a, ORF9b, or any other ORF of a SARS coronavirus now known or later identified, and any combination thereof and furthermore, wherein the order of nucleotide sequences of the cDNA encoding replication, accessory ORFs and/or structural proteins S, E, M and N is rearranged in comparison to the order in wild type SARS coronavirus. In this embodiment, the cDNA can further comprise an attenuating mutation in a consensus sequence of a nucleotide sequence of the cDNA, selected from the group consisting of a leader consensus sequence, an S consensus sequence, an ORF3a

consensus sequence, an E consensus sequence, an M consensus sequence, an ORF6 consensus sequence, an ORF7 consensus sequence, an ORF8 consensus sequence, an N consensus sequence, and any combination thereof.

5 The present invention also provides a SARS coronavirus replicon RNA comprising a coronavirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA lacks a sequence encoding at least one coronavirus structural protein.

10 Furthermore, the present invention provides an infectious, multiplication-defective, coronavirus particle, comprising a SARS coronavirus replicon RNA, wherein the replicon RNA comprises a coronavirus packaging signal and a heterologous RNA sequence, and wherein the replicon RNA lacks a sequence encoding at least one coronavirus structural protein.

15 Additionally provided is a population of infectious, multiplication defective, coronavirus particles, wherein each particle comprises a SARS coronavirus replicon RNA, and wherein the replicon RNA comprises a SARS coronavirus packaging signal and a heterologous RNA sequence, and wherein the replicon RNA lacks a sequence
20 encoding at least one coronavirus structural protein, wherein the population contains no detectable replication-competent coronavirus particles as determined by passage on coronavirus permissive cells in culture.

 The present invention further provides a method of introducing a heterologous
25 RNA into a subject, comprising administering to the subject an effective amount of the particles or populations and/or compositions of this invention.

 Also provided herein is a method of inducing an immune response and/or treating and/or preventing a SARS coronavirus infection in a subject, comprising
30 administering to the subject an effective amount of the viruses, vectors, particles or populations and/or compositions of this invention.

 In further embodiments, the present invention provides a helper cell for producing an infectious, multiplication-defective, coronavirus particle, comprising:

(a) a SARS coronavirus replicon RNA comprising a coronavirus packaging signal and a heterologous RNA sequence, wherein said replicon RNA lacks a sequence encoding at least one coronavirus structural protein; and/or (b) at least one separate helper RNA encoding the at least one coronavirus structural protein absent from the replicon RNA, said helper RNA lacking a coronavirus packaging signal; wherein the combined expression of the replicon RNA and the helper RNA produces an infectious, multiplication-defective coronavirus particle. Thus, the present invention includes the embodiment of a helper cell comprising a helper RNA encoding at least one coronavirus structural protein and the embodiment of a helper cell comprising a SARS coronavirus replicon RNA comprising a coronavirus packaging signal and a heterologous RNA sequence, wherein said replicon RNA lacks a sequence encoding at least one coronavirus structural protein.

The present invention additionally provides a method of making infectious, multiplication-defective, coronavirus particles, comprising: a) providing the helper cell of this invention; and b) producing coronavirus particles in the helper cell.

The foregoing and other objects and aspects of the present invention are explained in detail in the specification set forth below.

DETAILED DESCRIPTION OF THE INVENTION

"Nidovirus" as used herein refers to viruses within the order Nidovirales, including the families Coronaviridae and Arteriviridae. All viruses within the order Nidovirales share the unique feature of synthesizing a nested set of multiple subgenomic mRNAs. See M. Lai and K. Holmes, *Coronaviridae: The Viruses and Their Replication*, in *Fields Virology*, pg 1163, (4th Ed. 2001). Particular examples of Coronaviridae include, but are not limited to, toroviruses and coronaviruses.

"Coronavirus" as used herein refers to a genus in the family *Coronaviridae*, which family is in turn classified within the order Nidovirales. The coronaviruses are large, enveloped, positive-stranded RNA viruses. They have the largest genomes of all RNA viruses and replicate by a unique mechanism that results in a high frequency of recombination. The coronaviruses include antigenic groups I, II, and III. While

the present invention is described primarily with respect to SARS coronavirus, the invention may be carried out with any coronavirus, such as transmissible gastroenteritis virus (TGEV), human respiratory coronavirus, porcine respiratory coronavirus, canine coronavirus, feline enteric coronavirus, feline infectious
5 peritonitis virus, rabbit coronavirus, murine hepatitis virus, sialodacryoadenitis virus, porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, avian infectious bronchitis virus, and turkey coronavirus, as well as chimeras of any of the foregoing. *See generally* M. Lai and K. Holmes, "Coronaviridae: The Viruses and Their Replication," in Fields Virology, (4th Ed. 2001).

10

A "nidovirus permissive cell" or "coronavirus permissive cell" as used herein can be any cell in which a coronavirus can at least replicate, including both naturally occurring and recombinant cells. In some embodiments the permissive cell is also one that the nidovirus or coronavirus can infect. The permissive cell can be one that
15 has been modified by recombinant means to produce a cell surface receptor for the nidovirus or coronavirus.

A "heterologous RNA" as described herein can encode any protein, peptide, antisense sequence, ribozyme, etc., to be administered to a subject of this invention
20 for any purpose. For example, the heterologous RNA can encode, and be expressed in the subject to produce, a protein or peptide. The protein or peptide may, for example, be an antigen or immunogen in embodiments where it is desired to produce antibodies in an animal subject, which antibodies can be collected and used for diagnostic and/or therapeutic purposes, or where it is desired to elicit an immune
25 response to the protein or peptide in a subject.

A "structural protein" as used herein refers to a protein required for production of coronavirus particles of this invention, such as those encoded by the S, E, M and N genes, as well as any other structural proteins now known or later identified in the
30 coronavirus and in particular in the SARS virus genome. In embodiments of this invention wherein the replicon RNA and/or helper RNAs lack a nucleotide sequence encoding a structural protein, the nucleotide sequence can be wholly or partly deleted, or the sequence can be present but in a mutated form, so that the net effect is that the replicon RNA and/or the helper RNA is effectively incapable of producing the

necessary structural protein in functional form. Thus, for example, in an embodiment that recites a replicon RNA or helper RNA that "lacks a sequence encoding at least one coronavirus structural protein," it is meant that the nucleotide sequence encoding the at least one coronavirus structural protein is deleted completely or in part from the replicon RNA or helper RNA or it is meant that the nucleotide sequence encoding the at least one coronavirus structural protein is present on the replicon RNA or helper RNA but in a form (e.g., mutated or otherwise altered) that cannot be expressed to produce a functional protein.

"Multiplication-defective" or "replication-defective" as used herein means that the replicon RNA contained within viral particles produced according to the present invention does not itself contain sufficient genetic information to allow for the production of new infectious viral particles.

As noted above, the present invention is based on the discovery of a full-length cDNA of the SARS coronavirus. As used herein, a "cDNA of a SARS coronavirus" or "infectious cDNA of a SARS coronavirus" is a nucleic acid molecule comprising the nucleotide sequence of a SARS coronavirus, from which RNA transcripts are produced that replicate and/or are infectious *in vitro* or *in vivo*. A SARS coronavirus cDNA of this invention can encode the sequence of any SARS coronavirus isolate now known or later identified. The genomic sequences of some of the known SARS coronavirus isolates are set forth in Genbank and assigned Accession numbers AY278741 (SEQ ID NO:2, provided herein), AY274119, AY278554 and AY278554 and the entire contents of each of these sequences are incorporated by reference herein in their entireties as embodiments of this invention. (See also Rota et al. (2003) *Science* 300:1394; Marra et al. (2003) *Science* 300:1399; the entire contents of each of which are incorporated by reference herein for the teachings of the identification and characterization of the genomic sequence of a SARS coronavirus).

30

Two examples of a nucleic acid sequence encoding a cDNA of this invention are provided in the attached Sequence Listing as SEQ ID NO:1 and SEQ ID NO:3. As this invention encompasses all such cDNAs of all SARS coronavirus isolates, in one embodiment, the present invention provides an isolated nucleic acid comprising,

consisting of and/or consisting essentially of, a nucleotide sequence selected from the group consisting of: a) SEQ ID NO:1 and/or SEQ ID NO:3 or a fragment of at least 25 contiguous nucleotide sequences of SEQ ID NO:1 and/or SEQ ID NO:3; b) a nucleotide sequence that is functionally equivalent to the nucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3 but comprises different codons encoding the same amino acid sequences; c) a nucleotide sequence having at least 70% homology to the nucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3; d) a nucleotide sequence having at least 95% homology to the nucleotide sequence of SEQ ID NO:1 and/or SEQ ID NO:3; e) a nucleotide sequence that hybridizes to the complement of SEQ ID NO:1 and/or SEQ ID NO:3 under stringent conditions; and f) a nucleotide sequence having complementarity (e.g., partial or complete) to any of the nucleotide sequences of (a) – (e) above.

The present invention further provides nucleic acid molecules comprising, consisting of and/or consisting essentially of, a fragment of at least 25, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 950 or 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10,000, 15,000, 20,000, 25,000, 26,000, 27,000, 28,000, 29,000, 29,500, etc. contiguous nucleotides (including any values within this range not specifically recited herein, e.g., 56 nucleotides or 6345 nucleotides) of the nucleotide sequence of SEQ ID NO:1, or a complement thereof. A fragment of this invention can be a fragment that hybridizes to a sequence that is unique to the cDNA of this invention. The production, identification and characterization of such fragments for desired properties as described herein is carried out according to protocols well known in the art.

25

An "isolated" nucleic acid molecule is one that is chemically synthesized (e.g., derived from reverse transcription) or is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid molecule. Preferably, an "isolated" nucleic acid molecule is free of sequences (preferably protein encoding sequences) that naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kB, 4 kB, 3 kB, 2 kB, 1 kB, 0.5 kB or 0.1 kB of nucleotide sequences which naturally flank the nucleic acid molecule in genomic

DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. (e.g., as described in Sambrook et al., eds., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

In another embodiment of this invention, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence of SEQ ID NO:1 or a fragment thereof. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence under conditions described herein, thereby forming a stable duplex.

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence of SEQ ID NO:1 due to degeneracy of the genetic code and thus encode the same proteins as those encoded by the nucleotide sequence of SEQ ID NO:1.

In particular embodiments, a nucleic acid of this invention has at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more nucleic acid sequence homology with the sequences specifically disclosed herein. The term "homology" as used herein refers to a degree of similarity between two or more sequences. There can be partial homology or complete homology (*i.e.*, identity). A partially homologous sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization to the target sequence can be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-

specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (*i.e.*, selective) interaction. The absence of non-specific binding can be tested by the use of a second target sequence, which lacks even a partial degree of complementarity (*e.g.*, less than about 30% identity). In the
5 absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

Alternatively stated, in particular embodiments, nucleic acids encoding a cDNA of a SARS coronavirus that hybridize under the conditions described herein to
10 the complement of the sequences specifically disclosed herein can also be used according to the present invention. The term "hybridization" as used herein refers to any process by which a first strand of nucleic acid binds with a second strand of nucleic acid through base pairing.

15 The term "stringent" as used here refers to hybridization conditions that are commonly understood in the art to define the commodities of the hybridization procedure. High stringency hybridization conditions that will permit homologous nucleotide sequences to hybridize to a nucleotide sequence as given herein are well known in the art. As one example, hybridization of such sequences to the nucleic acid
20 molecules disclosed herein can be carried out in 25% formamide, 5X SSC, 5X Denhardt's solution and 5% dextran sulfate at 42°C, with wash conditions of 25% formamide, 5X SSC and 0.1% SDS at 42°C, to allow hybridization of sequences of about 60% homology. Another example includes hybridization conditions of 6X SSC, 0.1% SDS at about 45°C, followed by wash conditions of 0.2X SSC, 0.1% SDS
25 at 50-65°C. Another example of stringent conditions is represented by a wash stringency of 0.3 M NaCl, 0.03M sodium citrate, 0.1% SDS at 60-70°C using a standard hybridization assay (*see* SAMBROOK et al., EDS., MOLECULAR CLONING: A LABORATORY MANUAL 2d ed. (Cold Spring Harbor, NY 1989, the entire contents of which are incorporated by reference herein).

30

As is known in the art, a number of different programs can be used to identify whether a nucleic acid or amino acid has sequence identity or similarity to a known sequence. Sequence identity or similarity may be determined using standard techniques known in the art, including, but not limited to, the local sequence identity

algorithm of Smith & Waterman, *Adv. Appl. Math.* 2, 482 (1981), by the sequence identity alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48,443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Natl. Acad. Sci. USA* 85,2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, WI), the Best Fit sequence program described by Devereux *et al.*, *Nucl. Acid Res.* 12, 387-395 (1984), preferably using the default settings, or by inspection.

10 An example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, *J. Mol. Evol.* 35, 351-360 (1987); the method is similar to that
15 described by Higgins & Sharp, *CABIOS* 5, 151-153 (1989).

 Another example of a useful algorithm is the BLAST algorithm, described in Altschul *et al.*, *J. Mol. Biol.* 215, 403-410, (1990) and Karlin *et al.*, *Proc. Natl. Acad. Sci. USA* 90, 5873-5787 (1993). A particularly useful BLAST program is the WU-
20 BLAST-2 program that was obtained from Altschul *et al.*, *Methods in Enzymology*, 266, 460-480 (1996). WU-BLAST-2 uses several search parameters, which are preferably set to the default values. The parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of
25 interest is being searched; however, the values may be adjusted to increase sensitivity. An additional useful algorithm is gapped BLAST as reported by Altschul *et al.* *Nucleic Acids Res.* 25, 3389-3402.

 The CLUSTAL program can also be used to determine sequence similarity.
30 This algorithm is described by Higgins *et al.* (1988) *Gene* 73:237; Higgins *et al.* (1989) *CABIOS* 5:151-153; Corpet *et al.* (1988) *Nucleic Acids Res.* 16: 10881-90; Huang *et al.* (1992) *CABIOS* 8: 155-65; and Pearson *et al.* (1994) *Meth. Mol. Biol.* 24: 307-331.

The alignment may include the introduction of gaps in the sequences to be aligned. In addition, for sequences that contain either more or fewer nucleotides than the nucleic acids disclosed herein, it is understood that in one embodiment, the percentage of sequence identity will be determined based on the number of identical
5 nucleotides in relation to the total number of nucleotide bases. Thus, for example, sequence identity of sequences shorter than a sequence specifically disclosed herein will be determined using the number of nucleotide bases in the shorter sequence, in one embodiment. In percent identity calculations, relative weight is not assigned to various manifestations of sequence variation, such as, insertions, deletions,
10 substitutions, *etc.*

In certain embodiments of this invention, the nucleic acid of this invention can comprise a promoter that directs the production of an RNA transcript from the cDNA. This promoter can be active *in vitro* or *in vivo* to produce an RNA transcript from the
15 SARS coronavirus cDNA that can replicate and/or is infectious. Non-limiting examples of the promoter of this invention include a T7 promoter, a SP6 promoter a T3 promoter, a CMV promoter, a MoMLV promoter, a metallothionein promoter, a glucocorticoid promoter, a SV40 promoter, a CaMV 35S promoter, a nopaline synthetase promoter, and any other promoter that directs RNA transcription *in vitro* or
20 in a cell.

Also provided herein is an RNA and a SARS coronavirus particle produced by the cDNA of this invention and a SARS coronavirus particle comprising the RNA produced from the cDNA of this invention. Further provided herein is a vector
25 comprising the cDNA or RNA of this invention and a cell comprising the vector of this invention.

The present invention further provides a cDNA of a SARS coronavirus, wherein all or part of a nucleotide sequence of the cDNA is deleted and wherein the
30 nucleotide sequence is selected from the group consisting of a nucleotide sequence encoding ORF1, ORF2, ORF3a, ORF3b, ORF4, ORF5, ORF6, ORF7a/b, ORF8a/b, ORF9a, ORF9b, any other ORF of a SARS coronavirus now known or later identified, and any combination thereof. It is also intended that the ORF sequence of this invention can be intact but altered to have the same effect as a total or partial

deletion. Methods of deleting all or part of an ORF and/or altering an ORF of a cDNA of a SARS coronavirus of this invention and testing the resulting genotype and phenotype are set forth in the Examples and such methods are also routine to one of ordinary skill in the art. Examples of deletion mutants of this invention are provided in the Sequence Listing provided herein as SEQ ID NOs:4-9. These are sequences of subclone F having deletions in ORFX1 (SEQ ID NO:4), ORFX1 and X2 (SEQ ID NO:5), ORFX3 (SEQ ID NO:6), ORFX4 (SEQ ID NO:7) ORFX4 substituted with green fluorescent protein (GFP) (SEQ ID NO:8) and ORFX4 substituted with luciferase (SEQ ID NO:9).

10

Further provided herein is a cDNA of a SARS coronavirus, comprising a mutation in a nucleotide sequence selected from the group consisting of a nucleotide sequence encoding ORF1, ORF2, ORF3a, ORF3b, ORF4, ORF5, ORF6, ORF7a/b, ORF8a/b, ORF9a, ORF9b, ORF 10, ORF 13, ORF 14, any other ORF of a SARS coronavirus, and any combination thereof, wherein the mutation results in a nonfunctional gene product. Methods of producing the various mutants of this invention and testing the resulting genotype and phenotype are set forth in the Examples provided herein and such methods are also routine to one of ordinary skill in the art.

20

In additional embodiments, the present invention provides a cDNA of a SARS coronavirus, wherein the order of nucleotide sequences encoding replicase, accessory ORFs and/or structural proteins S, E, M and N is rearranged in comparison to the order in wild type SARS coronavirus. In addition, or alternatively, one or more of the nucleotide sequences encoding replicase, accessory ORFs and/or structural proteins S, E, M and N can be present two or more times on the cDNA. Nonlimiting examples of these embodiments include cDNAs wherein the order of nucleotide sequences encoding structural proteins is: a) 5' S, N, E and M 3', b) 5' N, S, E and M 3', c) 5' E, M, S and N 3', d) 5' E, M, N and S 3', e) 5' S, N, E, M, N 3'. These examples are provided to show the order of the nucleotide sequences encoding the structural proteins S, E, M and N, relative to one another, with respect to the 5' and 3' ends of the cDNA molecule. However, these examples are not intended to be limiting in any way with respect to the positioning of the replicase, accessory ORFs and/or any other coding sequences present in the cDNA sequence. Thus, for example, the replicase,

25
30

accessory ORFs and/or other coding sequences present in the cDNA sequence can be positioned anywhere (e.g., before, after, in multiple repeats before and/or after) relative to the each of the coding sequences of the S, E, M and N proteins. Furthermore, any of the coding sequences of the structural proteins, replicase,
5 accessory ORFs and/or other coding sequences can be modified by mutation and/or deletion in this embodiment.

The present invention also provides a cDNA of a SARS coronavirus, comprising an attenuating mutation in a consensus sequence, ACGAAC, which can
10 be, but is not limited to, a leader consensus sequence, an S (ORF2) consensus sequence, an ORF3a consensus sequence, an E consensus sequence, an M consensus sequence, an ORF6 consensus sequence, an ORF7 consensus sequence, an ORF8 consensus sequence, an N consensus sequence, and any combination thereof. The mutations of this invention can also include any mutation in any combination of the
15 six consensus nucleotides and the surrounding flanking nucleotides (+/- 50 nucleotides) that function as regulatory junctions to direct transcription of full length and subgenomic mRNAs. Two nonlimiting examples of mutations in the consensus sequence include "ACGAAC" to "ACCAAC" and "ACGAAC" to AGGAAG." Other examples of mutations of this invention are provided in Tables 1 and 2.

20

Further provided herein is a cDNA of a SARS coronavirus comprising a 29 bp insertion in ORF8a/b, or any other modification or alteration that reproduces a full length ORF8 protein sequence. In some embodiments, the full length ORF8 protein sequence provides an attenuating phenotype to the SARS coronavirus.

25

In additional embodiments, the present invention provides a cDNA of a SARS coronavirus wherein all or part of a nucleotide sequence of the cDNA is deleted and wherein the nucleotide sequence is selected from the group consisting of a nucleotide sequence encoding ORF1, ORF2, ORF3a, ORF3b ORF4, ORF5, ORF6, ORF7a/b,
30 ORF8a/b, ORF9a, ORF9b, any other ORF of a SARS coronavirus now known or later identified, and any combination thereof and furthermore, wherein the order of nucleotide sequences of the cDNA encoding replication, accessory ORFs and/or structural proteins S, E, M and N is rearranged in comparison to the order in wild type SARS coronavirus. In some variations of this embodiment, it is also contemplated

that the cDNA can further comprise an attenuating mutation in a consensus sequence of a nucleotide sequence of the cDNA selected from the group consisting of a leader consensus sequence, an S consensus sequence, an ORF3a consensus sequence, an E consensus sequence, an M consensus sequence, an ORF6 consensus sequence, an
5 ORF7 consensus sequence, an ORF8 consensus sequence, an N consensus sequence and any combination thereof.

Furthermore, in additional embodiments, the present invention provides a SARS coronavirus replicon RNA comprising a coronavirus (e.g., SARS) packaging
10 signal and a heterologous RNA sequence, wherein the replicon RNA lacks a sequence encoding at least one coronavirus structural protein.

Further provided herein is a DNA encoding a replicon RNA of this invention. In certain embodiments, the DNA can comprise a promoter to direct the transcription
15 of the RNA, either *in vitro* or within a cell.

The present invention additionally provides an infectious, multiplication-defective, coronavirus particle, comprising a SARS coronavirus replicon RNA, wherein the replicon RNA comprises a coronavirus (e.g., SARS) packaging signal and
20 a heterologous RNA sequence, and wherein the replicon RNA lacks a sequence encoding at least one coronavirus structural protein.

In some embodiments, the replicon RNA of this invention can comprise a nucleic acid sequence encoding at least one coronavirus structural protein, provided
25 the replicon RNA does not comprise nucleic acid sequences functionally encoding all of the coronavirus structural proteins. In other embodiments, the replicon RNA can comprise a promoter. In yet other embodiments, the replicon RNA may or may not comprise a nucleic acid sequence encoding a replicase protein. It is also contemplated that the replicon RNA can lack a coronavirus packaging signal under circumstances
30 wherein the replicon RNA is packaged into coronavirus particles nonspecifically or under conditions wherein it is contacted with a coronavirus structural protein comprising a nucleic acid binding site that facilitates packaging of the replicon RNA in the absence of a coronavirus packaging signal.

It is also an embodiment of this invention wherein the nucleic acid of the replicon RNA encodes, and/or the particle itself comprises, a coronavirus structural protein that is produced from nucleic acid of a coronavirus that can be, but is not limited to, SARS coronavirus, human respiratory coronavirus, mouse hepatitis virus, porcine transmissible gastroenteritis virus, porcine respiratory coronavirus, canine coronavirus, feline enteric coronavirus, feline infectious peritonitis virus, rabbit coronavirus, murine hepatitis virus, sialodacryoadenitis virus, porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, avian infectious bronchitis virus, turkey coronavirus and/or any other coronavirus now known or later identified, as well as any combination thereof, thereby resulting in chimeric coronavirus particles.

In embodiments wherein one or more of the structural proteins are from different coronaviruses in a particle and/or one or more structural proteins are encoded by the nucleic acid of the replicon RNA, the coronavirus structural protein encoded by the nucleic acid of the replicon RNA can be S, E, M, N or combinations thereof.

The coronavirus packaging signal of this invention can be a packaging signal of any coronavirus now known or later identified. For example, the packaging signal can be from a coronavirus that can be, but is not limited to, SARS coronavirus, human respiratory coronavirus, mouse hepatitis virus, porcine transmissible gastroenteritis virus, porcine respiratory coronavirus, canine coronavirus, feline enteric coronavirus, feline infectious peritonitis virus, rabbit coronavirus, murine hepatitis virus, sialodacryoadenitis virus, porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, avian infectious bronchitis virus, turkey coronavirus.

Further provided herein is a population of infectious, multiplication defective, coronavirus particles, wherein each particle comprises a SARS coronavirus replicon RNA, and wherein the replicon RNA comprises a coronavirus (e.g., SARS) packaging signal and a heterologous RNA sequence, and wherein the replicon RNA lacks a sequence encoding at least one coronavirus structural protein, wherein the population contains no detectable replication-competent coronavirus particles as determined by passage on coronavirus permissive cells in culture. Methods of detecting replication

competent particles by passage on cell culture are standard in the art. These assays can also be carried out by passage of the replicon particles of this invention on cells constitutively expressing nucleic acid encoding the missing coronavirus structural protein(s), with the expected result of obtaining replication competent coronavirus
5 particles.

It is also contemplated that the replicon RNA and/or replicon particles of this invention can comprise coronavirus RNA and/or structural proteins that comprise any or all of the gene order rearrangements, deletions and/or mutations described herein
10 that can be present in the SARS coronavirus cDNA of this invention.

The viruses, vectors, particles and populations are intended for use as therapeutic agents and immunological reagents, for example, as antigens, immunogens, vaccines, and/or nucleic acid delivery vehicles. Thus, in various
15 embodiments, the present invention provides a composition comprising the virus, vector, particle, and/or population of this invention in a pharmaceutically acceptable carrier. The compositions described herein can be formulated for use as reagents (e.g., to produce antibodies) and/or for administration in a pharmaceutical carrier in accordance with known techniques. *See, e.g., Remington, The Science And Practice*
20 *of Pharmacy* (latest edition). In the manufacture of a pharmaceutical composition according to embodiments of the present invention, the composition of this invention is typically admixed with, *inter alia*, a pharmaceutically acceptable carrier. By "pharmaceutically acceptable carrier" is meant a carrier that is compatible with other ingredients in the pharmaceutical composition and that is not harmful or deleterious to
25 the subject. The carrier may be a solid or a liquid, or both, and is preferably formulated with the composition of this invention as a unit-dose formulation. The pharmaceutical compositions are prepared by any of the well-known techniques of pharmacy including, but not limited to, admixing the components, optionally including one or more accessory ingredients. Exemplary pharmaceutically acceptable
30 carriers include, but are not limited to, sterile pyrogen-free water and sterile pyrogen-free physiological saline solution. Such carriers can further include protein (e.g., serum albumin) and sugar (sucrose, sorbitol, glucose, etc.)

The pharmaceutical compositions of this invention include those suitable for oral, rectal, topical, inhalation (e.g., via an aerosol) buccal (e.g., sub-lingual), vaginal, parenteral (e.g., subcutaneous, intramuscular, intradermal, intraarticular, intrapleural, intraperitoneal, intracerebral, intraarterial, or intravenous), topical (i.e., both skin and
5 mucosal surfaces, including airway surfaces) and transdermal administration. The compositions herein may also be administered via a skin scarification method, or transdermally via a patch or liquid. The compositions may be delivered subdermally in the form of a biodegradable material that releases the compositions over a period of time. The most suitable route in any given case will depend, as is well known in the
10 art, on such factors as the species, age, gender and overall condition of the subject, the nature and severity of the condition being treated and/or on the nature of the particular composition (i.e., dosage, formulation) that is being administered.

Subjects to whom the viruses, vectors, particles, populations and/or other
15 compositions of this invention can be administered according to the methods described herein can be any subject, generally vertebrates, for which the particles, populations and/or compositions are infectious, including but not limited to, birds and mammals such as pigs, mice, cows, and humans.

20 As used herein, an "effective amount" refers to an amount of a compound or composition that is sufficient to produce a desired effect, which can be a therapeutic, prophylactic and/or beneficial effect.

Thus, the present invention provides a method of inducing an immune
25 response in a subject, comprising administering to the subject an effective amount of a virus, vector, particle, population and/or composition of this invention.

The present invention also provides a method of treating and/or preventing a
SARS coronavirus infection in a subject, comprising administering to the subject an
30 effective amount of a virus, vector, particle, population and/or composition of this invention.

Also as used herein, the terms "treat," "treating" and "treatment" include any type of mechanism, action or activity that results in a change in the medical status of a

subject, including an improvement in the condition of the subject (*e.g.*, change or improvement in one or more symptoms and/or clinical parameters), delay in the progression of the condition, prevention or delay of the onset of a disease or illness, etc.

5 One example of an effective amount is from about 10^4 to about 10^{10} , preferably 10^5 to 10^9 , and in particular 10^6 to 10^8 infectious units (IU, as measured by indirect immunofluorescence assay), or virus particles, per dose, which can be administered to a subject, depending upon the age, species and/or condition of the subject being treated.

10

 In some embodiments of the present invention, the compositions can be administered with an adjuvant. As used herein, "adjuvant" describes a substance, which can be any immunomodulating substance capable of being combined with the polypeptide or nucleic acid vaccine to enhance, improve or otherwise modulate an
15 immune response in a subject without deleterious effect on the subject.

 Non-limiting examples of adjuvants that can be used in the vaccine of the present invention include the RIBI adjuvant system (Ribi Inc., Hamilton, Mont.), alum, mineral gels such as aluminum hydroxide gel, oil-in-water emulsions, water-in-
20 oil emulsions such as, *e.g.*, Freund's complete and incomplete adjuvants, Block copolymer (CytRx, Atlanta Ga.), QS-21 (Cambridge Biotech Inc., Cambridge Mass.), SAF-M (Chiron, Emeryville Calif.), AMPHIGENTM adjuvant, saponin, Quil A or other saponin fraction, monophosphoryl lipid A, and Avridine lipid-amine adjuvant. Non-limiting examples of oil-in-water emulsions useful in the vaccine of the
25 invention include modified SEAM62 and SEAM 1/2 formulations. Modified SEAM62 is an oil-in-water emulsion containing 5% (v/v) squalene (Sigma), 1% (v/v) SPANTM 85 detergent (ICI Surfactants), 0.7% (v/v) TWEENTM 80 detergent (ICI Surfactants), 2.5% (v/v) ethanol, 200 µg/ml Quil A, 100 µg/ml cholesterol, and 0.5% (v/v) lecithin. Modified SEAM 1/2 is an oil-in-water emulsion comprising 5% (v/v)
30 squalene, 1% (v/v) SPANTM 85 detergent, 0.7% (v/v) Tween 80 detergent, 2.5% (v/v) ethanol, 100 µg/ml Quil A, and 50 µg/ml cholesterol. Other immunomodulatory agents that can be included in the vaccine include, *e.g.*, one or more interleukins, interferons, or other known cytokines.

SARS coronavirus vectors also provide a system for the incorporation and expression of one or more heterologous nucleic acids, as coronaviruses contain a polycistronic genome organization and synthesize multiple subgenomic-length mRNAs (Enjuanes and van der Zeijst (1995) *In: S.G. Siddell (ed.), The*
5 *Coronaviridae*. Plenum Press, New York, NY, p. 337-376).

In certain embodiments, the present invention describes the assembly of recombinant transmissible virus and replicons that express heterologous nucleic acids, which can be used to deliver such nucleic acids and/or make vaccines/immunogenic
10 compositions against homologous and heterologous pathogens (Agapov et al. (1998) *Proc. Natl. Acad. Sci. USA* 95:12989-12994; Balasuriya et al. (2000) *J. Virol.* 74:10623-10630; Berglund et al. (1998) *Nat. Biotechnol.* 16:562-565; Bredenbeek et al. (1993) *J. Virol.* 67:6439-6446; DiCiommo and Bremner (1998) *J. Biol. Chem.* 273:18060-18066; Dollenmaier et al. (2001) *Virology* 281:216-230; Dubensky et al.
15 (1996) *J. Virol.* 70:508-519; Hevey et al. (1998) *Virology* 251:28-37; Johanning et al. (1995) *Nucleic Acids Res.* 23:1495-1501; Khromykh (2000) *Curr. Opin. Mol. Ther.* 2:555-569; Khromykh and Westaway (1997) *J. Virol.* 71:1497-1505; Liljestrom and Garoff (1991) *Bio/Technology* 9:1356-1361; Percy et al. (1992) *J. Virol.* 66:5040-5046; Porter, et al. (1993) *J. Virol.* 67:3712-3719; Pushko et al. (2000) *Vaccine*
20 19:142-153; Schultz-Cherry et al (2000) *Virology* 278:55-59; Varnavski and Khromykh (1999) *Virology* 255:366-375; Varnavski et al. (2000) *J. Virol.* 74:4394-4403).

The use of replicons as a vaccine delivery system offers a number of important
25 advantages over the use of live, attenuated virus vaccines, which are capable of independent spread and recombination with wild-type virus populations. Replicon vectors are an inherently safer alternative to the use of live, attenuated virus vaccines due to the lack of progeny virus production. In addition, high-level expression of heterologous nucleic acids can result in the use of a relatively low dose of virus
30 replicon particles (VRPs) for vaccination and immune induction. Moreover, gene order rearranged and/or otherwise attenuated replicon particles will be inherently more stable and less pathogenic than attenuated wild-type strains.

Thus, the present invention also provides a method of introducing a heterologous RNA into a subject, comprising administering to the subject an effective amount of the particles and/or the populations and/or compositions of this invention comprising these particles or populations. The heterologous RNA can encode any protein or peptide or antisense sequence or ribozyme and can be administered to
5 impart any type of effect (e.g., immunological or therapeutic, etc.).

The production of virus replicon particles is well known in the art for a variety of virus systems, including coronaviruses (see, e.g., Curtis et al. (2002) *J. Virol.* 76:1422-1434; PCT Publication No. WO 02/086068, the entire contents of each of
10 which are incorporated by reference herein). The present invention can also be implemented in any of a variety of ways, including by techniques, compositions and formulations known in the art (see, e.g., U.S. Patent No. 6,593,311 to Baric et al.; U.S. Patent No. 6,156,558 to Johnston et al.; and U.S. Patent No. 5,639,650 to
15 Johnston et al.; U.S. Patent No. 6,342, 372 to Dubensky et al.) modified in light of the teachings set forth herein. Applicants specifically intend that the disclosures of all United States patent references and patent publications cited herein be incorporated herein by reference in their entirety.

20 The synthesis of large RNA transcripts (~27 to 29 kb) *in vitro* is problematic, and the electroporation of such large RNA constructs, even in the presence of enhancing N transcripts, has also proven difficult, resulting in a 1% transfection efficiency. Therefore, transfecting cells with helper packaging constructs and subsequently passing the coronavirus VRPs in the presence of VEE-(E) VRPs can
25 address this issue. In this way, VRPs can be amplified and high concentrations may amplify replicon titers for future applications. In addition, the use of a DNA launch platform, such as with a cytomegalovirus promoter, may be used to overcome any problems associated with an RNA launch system.

30 The strategy presented herein for the assembly of SARS replicon constructs was based on a similar strategy for the construction of TGEV cDNA, employing six cDNA subclones that span the entire length of the SARS genome (see Yount et al. *J. Virol.* 74:10600-10611 (2000)). Each fragment is flanked by restriction sites that leave unique interconnecting junctions of 3 or 4 nt in length. These sticky ends are

not complementary to most other sticky ends generated with the same enzyme at other sites in the DNA, allowing for the systematic assembly of SARS cDNAs by *in vitro* ligation.

5 The infectious, replication defective, coronavirus particles can be prepared according to the methods disclosed herein in combination with techniques known to those skilled in the art. As one example, the method can comprise a) introducing into a coronavirus-permissive cell 1) a SARS coronavirus replicon RNA comprising a coronavirus packaging signal and a heterologous RNA, a first helper RNA encoding
10 at least one coronavirus structural protein and a second (and possibly third, fourth, etc.) helper RNA encoding at least one coronavirus structural protein that is different from that encoded by the first helper RNA; b) producing the coronavirus particles in the cell; and c) optionally collecting the particles from the cell. The step of introducing the replicon RNA and helper RNA(s) into the coronavirus-permissive cell
15 can be carried out according to any suitable means known to those skilled in the art. For example, uptake of the RNA into the cell can be achieved by any suitable means, such as for example, by treating the cells with DEAE-dextran, treating the cells with "LIPOFECTIN™," and/or by electroporation, with electroporation being the currently preferred means. These techniques are well known in the art. See e.g., U.S. Pat. No.
20 5,185,440 to Davis et al., and PCT Publication No. WO 92/10578 to Bioption AB, the disclosures of which are incorporated herein by reference in their entirety. Alternatively, a DNA encoding the replicon RNA and/or a DNA encoding the helper RNA(s) can be introduced into the cell according to known methods and the DNA can be transcribed into RNA within the cell.

25

 The present invention also provides methods for producing SARS coronavirus replicon particles, as well as helper RNAs and helper cells employed in the production. Thus, in further embodiments, the present invention provides a helper cell for producing an infectious, multiplication-defective, coronavirus particle,
30 comprising: (a) a SARS coronavirus replicon RNA comprising a SARS coronavirus packaging signal and a heterologous RNA sequence, wherein said replicon RNA further lacks a sequence encoding at least one coronavirus structural protein; and (b) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, said helper RNA lacking a coronavirus packaging signal;

wherein the combined expression of the replicon RNA and the helper RNA produces an infectious, multiplication-defective coronavirus particle.

As noted above, the replicon RNA can further comprise a sequence encoding
5 at least one of the coronavirus structural proteins, provided that the replicon RNA does not comprise nucleic acid encoding all of the coronavirus structural proteins.

In the helper cells of this invention, the helper RNA can comprise a nucleic acid sequence encoding a coronavirus structural protein that can be E, M, N, S, or any
10 combination thereof, provided that the helper RNA does not comprise nucleic acid encoding all of the coronavirus structural proteins. The nucleic acid encoding the coronavirus structural protein can be from a coronavirus that can be SARS coronavirus, human respiratory coronavirus, mouse hepatitis virus, porcine transmissible gastroenteritis virus, porcine respiratory coronavirus, canine
15 coronavirus, feline enteric coronavirus, feline infectious peritonitis virus, rabbit coronavirus, murine hepatitis virus, sialodacryoadenitis virus, porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, avian infectious bronchitis virus, turkey coronavirus and/or any other coronavirus now known or later identified, as well as combinations thereof, thereby resulting in chimeric coronavirus
20 particles.

Furthermore, the helper RNA can comprise nucleic acid of any other non-coronavirus, including, but not limited to, vaccinia virus, alphavirus, flavivirus, vesicular stomatitis virus, poxvirus, adenovirus, herpesvirus, paramyxovirus,
25 parvovirus, papovavirus,, adeno-associated virus, and retrovirus. The helper RNA can also be a vector of non-viral origin that provides nucleic acid encoding the coronavirus structural protein(s) not present on the replicon RNA in the helper cell.

In certain embodiments, the replicon RNA and/or the helper RNA contains at
30 least one attenuating gene order rearrangement among the 3A, 3B, HP, S, E, M and N genes. Helper or replicon RNAs (and their corresponding DNAs) that contain two or more genes optionally but preferably include a gene order rearrangement to attenuate (*e.g.*, reduce the virulence) as compared to a corresponding wild-type virus that does not contain such a gene order rearrangement (*i.e.*, comparing a virus with all of the

necessary genes and the order rearrangement with a wild-type virus). Depending upon the number of genes within the helper or replicon RNA, it may contain two, three, or four or more gene order rearrangements. The wild-type gene order, from 5' to 3', is:: S, 3A, 3B, E, M, N, and HP. For example, modified orders for the replicon RNA, when the helper RNA(s) contains the E gene, may include: S, 3B, M, N, HP and 3A; 3A, 3B, M, N, HP and S; S, 3A, 3B, N, HP, and M; etc. In other embodiments, the E gene may be provided alone on the replicon RNA, and the helper RNA(s) may contain the genes described above in the orders given above. Modified orders for the replicon RNA, when the helper RNA(s) contains the M and N (in natural or reverse order) genes, may include: 3A, 3B, E, S and HP; S, E, 3A, 3B, and HP; S, 3A, 3B, E, and HP; S, E, HP, 3A, and 3B, etc. In other embodiments, the replicon RNA may contain the M and N genes (in natural or reverse orders), and the remaining genes may be provided on the helper RNA(s) in orders such as given above. In still other embodiments, where the helper RNA(s) contains the S gene, the replicon RNA may contain the remaining genes in the order 3B 3A, E, M, N, and HP; 3A, 3B, E, N, M, and HP; 3B, 3A, E, N, M, and HP; etc. Again, the replicon RNA may contain the S gene, and the helper RNA(s) may contain the remaining genes in the orders given above. The 3A, 3B, and HP genes are nonessential and some or all may be deleted, or they may be included in an alternate order to serve as attenuating mutations. The genes may be divided among multiple helper RNAs, some or all of which contain gene order rearrangements. The foregoing examples are merely illustrative, and numerous additional variations will be readily apparent to those skilled in the art.

In other embodiments, an attenuating mutation can be introduced by deleting one or more of the nonessential genes 3A, 3B, and HP.

In additional embodiments of the helper cells of this invention, the helper RNA(s) and/or the replicon RNA can comprise a promoter.

Additionally provided herein as an embodiment of this invention is a DNA encoding a helper RNA of this invention and a helper cell comprising said helper RNA-encoding DNA, as well as a DNA encoding a replicon RNA of this invention and a helper cell comprising said replicon-encoding DNA. The DNA can be present in the cell transiently or in a stably transformed state. The DNAs of this invention can

further comprise a promoter to direct the transcription of the helper RNA and the replicon RNA, respectively, in the helper cell.

5 A further embodiment of this invention is a method of making infectious, multiplication-defective, coronavirus particles, comprising: a) providing the helper cells of this invention: and b) producing coronavirus particles in the helper cell. Optionally, the particles can be collected from the cells.

10 In certain embodiments, the helper cell can be provided by introducing the replicon RNA and/or the helper RNA into the helper cell by electroporation. However, the replicon RNA and/or helper RNA, as well as their respective DNAs can be introduced into the helper cell according to any methods known in the art for introducing nucleic acid into a cell. The nucleic acids can be present in the helper cell transiently or as stable transformants.

15

The present invention additionally provides infectious coronavirus particles produced by the methods of this invention.

20 The step of producing the infectious viral particles in the helper cells can also be carried out using conventional techniques. See e.g., U.S. Pat. No. 5,185,440 to Davis et al., PCT Publication No. WO 92/10578 to Bioption AB, and U.S. Pat. No. 4,650,764 to Temin et al. (although Temin et al. relates to retroviruses rather than coronaviruses). The infectious viral particles may be produced by standard cell culture growth techniques.

25

The step of collecting the infectious coronavirus particles can also be carried out using conventional techniques. For example, the infectious particles can be collected by cell lysis, or collection of the supernatant of the cell culture, as is known in the art. See e.g., U.S. Pat. No. 5,185,440 to Davis et al., PCT Publication No. WO 30 92/10578 to Bioption AB, and U.S. Pat. No. 4,650,764 to Temin et al. (although Temin et al. relates to retroviruses rather than coronaviruses). Other suitable techniques will be known to those skilled in the art. Optionally, the collected infectious coronavirus particles can be purified if desired. Suitable purification techniques are well known to those skilled in the art.

In some embodiments, VEE replicon vectors can be used to express coronavirus structural genes in producing combination vaccines. Dendritic cells, which are professional antigen-presenting cells and potent inducers of T-cell responses to viral antigens, are preferred targets of VEE and VEE replicon particle infection, while SARS coronavirus targets the mucosal surfaces of the respiratory and gastrointestinal tract. As the VEE and SARS replicon RNAs synergistically interact, two-vector vaccine systems are feasible that may result in increased immunogenicity when compared with either vector alone. Combination prime-boost vaccines (e.g., DNA immunization and vaccinia virus vectors) have dramatically enhanced the immune response (notably cellular responses) against target papillomavirus and lentivirus antigens compared to single-immunization regimens (Chen et al. (2000) *Vaccine* 18:2015-2022; Gonzalo et al. (1999) *Vaccine* 17:887-892; Hanke et al. (1998) *Vaccine* 16:439-445; Pancholi et al. (2000) *J. Infect. Dis.* 182:18-27). Using different recombinant viral vectors (influenza and vaccinia) to prime and boost may also synergistically enhance the immune response, sometimes by an order of magnitude or more (Gonzalo, et al. (1999) *Vaccine* 17:887-892). Thus, the present invention also provides methods of combining different recombinant viral vectors (e.g., VEE and SARS) in prime boost protocols.

20

The examples, which follow, are set forth to illustrate the present invention, and are not to be construed as limiting thereof. In the following examples, mM means millimolar, μ g means microgram, ml means milliliter, μ l means microliter, V means volt, μ F means microfarad, cm means centimeter, h means hour, ORF means open reading frame, GFP means green fluorescent protein, PBS means phosphate-buffered saline, M means molar, s means second, nt means nucleotide, and min means minute.

25

EXAMPLES

Example 1. Production of full-length infectious cDNA of SARS coronavirus

Virus and Cells. The Urbani, Tor-2 and Tor-7 Canadian strains of SARS-CoV were propagated on VeroE6 cells in Eagle's MEM supplemented with 10% fetal calf serum and kanamycin (0.25 μ g/ml) and gentamycin (0.05 μ g/ml) at 37°C in a humidified CO₂ incubator (Tor isolates were kindly provided by H. Feldmann). For virus growth,

30

cultures of VeroE6 cells were infected at a multiplicity of infection (MOI) of 5 for 1 hr and samples were titered by plaque assay. At 1 hr postinfection, some cultures were treated with the cysteine protease inhibitor E64-d ({2S, 3S}-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester) at a concentration of 500
 5 µg/ml. Virus plaques were visualized by neutral red staining at 2 days postinfection.

Strategy for Cloning the SARS-CoV cDNAs. Reverse transcription was performed using Superscript II™, oligodeoxynucleotide primers and intracellular RNA from SARS infected cultures [17, 18]. The cDNA was denatured for 2 min at 94°C and
 10 amplified by PCR with Expand Long TAQ polymerase (Boehringer Mannheim Biochemical) for 25 cycles at 94°C for 30 sec, 58°C for 25-30 sec and 68°C for 1-7 min. The amplicons were cloned into Topo II TA (Invitrogen) (SARS subclones D-F) or in pSMART vectors (Lucigen) (SARS subclones A-C). All cDNAs were assembled as consensus sequences based on independent sequence analysis of 4-7 sibling clones
 15 and the reported Urbani sequence [8]. The following primers were used in the isolation of the SARS A subclone (forward: tactaatacgaactcactatagatattagggttttacctaccagg-1; reverse: acaccatagtcacgatgcc-4452), SARS B subclone (forward: gcctatatgcatggatgtagat-4359; reverse: tgaaccgccacgctggctaaacc-8727), SARS C subclone (forward: agccagcgtggcggttcatac-
 20 8710; reverse:aggcctcttgggcagtggcataag-12,085), SARS D subclone (forward: actgcccaagatgcctatgagc-12,070; reverse: cagccaggagggcagacttcacaacc-18,939), SARS E subclone (forward: gtctgccctcctggctgataagttccag-18,923; reverse: gagcagccgtgtaggcagcaat-24066) and SARS F subclone (forward: attgctgcctacacggctgctc-24,045; reverse: (ttt)₇gtcattctcctaagaagc-29,710).

25 To repair sibling clones, primer pairs were designed that contained a Class IIS restriction enzyme (e.g., AarI). Using high fidelity PCR, the consensus portions of different sibling clones were amplified, digested with AarI and ligated into plasmid. The AarI junctions were designed to seamlessly link consensus fragments, resulting in the production of a full-length cDNA [17]. Using an automated ABI DNA sequencer, 2-3 candidate DNAs
 30 were sequenced to identify the consensus clone.

Systematic Assembly of a Full-Length SARS-CoV cDNA. The SARS A through F inserts were restricted, separated through 0.8% agarose gels, visualized with a

Darkreader Lightbox (Claire Chemical), excised, and purified using the Qiaex II DNA purification kit. The SARS A+B, C+D and E+F subclones were ligated overnight and isolated [17, 18]. The SARS AB+CD+EF cDNAs were ligated overnight at 4°C, phenol/chloroform extracted and precipitated under isopropyl alcohol. Full-length transcripts were generated *in vitro* as described by the manufacturer (Ambion, mMessage mMachine) with certain modifications [17]. For SARS N transcripts, 1 µg of plasmid DNA encoding the N gene (primer: 5'nnggcctcgatggccatttagtgacactatagatgtctgataatggacccaatc-3' and reverse primer 5'-nnntttttttttttttttttttatgcctgagtgatcagcag-3') was transcribed by SP6 RNA polymerase with a 2:1 ratio of cap analog to GTP.

Transfection of Full-Length Transcripts. RNA transcripts were added to 800 µl of the BHK cell suspension (8.0×10^6) in an electroporation cuvette and three electrical pulses of 850 V at 25 µF were given with a Gene Pulser II electroporator (BioRad) [17, 18]. The transfected BHK cells were seeded with $1.0\text{-}2.0 \times 10^6$ uninfected Vero E6 cells in a 75cm² flask and incubated at 37°C for 2 days. Virus progeny were then passaged in Vero E6 cells at ~30 hr intervals and purified by plaque assay.

Detection of Marker Mutations Inserted in icSARS-CoV. Intracellular RNA was isolated from either wild type or icSARS-CoV infected cells at 24 hrs postinfection. After RT-PCR, a 1668 nt amplicon (nt position 1007-2675) was obtained, spanning the BglI site at position 1572 that had been ablated in the icSARS-CoV component clones, but not wild type SARS-CoV. Other PCR products included a 799 nt amplicon spanning the SARS-CoV B/C junction (nt position 8381-9180), a 544 nt amplicon (nt position 11,721-12,265) spanning the SARS-CoV C/D junction, a 652 nt amplicon spanning the SARS-CoV D/E junction, and a 1594 nt amplicon (nt position 23,665-25,259) spanning the SARS-CoV E/F junction. The 1594 nt SARS E/F junction-containing amplicon was subcloned and sequenced.

RT-PCR of Leader-containing Transcripts. Leader containing amplicons were obtained from wild type and icSARS-CoV infected cells using primers at the 3' end of the genome (5'-ttttttttttttttttttgtcattctcctaagaagc-3') and in the SARS leader RNA

sequence (5'-aaagccaaccaacctcgatc-3'). Leader-containing amplicons were excised from gels, subcloned into TopoII vectors and sequenced using appropriate primers.

Assembly of Coronavirus Full Length cDNAs. Rapid response and control of
5 exigent emerging pathogens requires an approach to rapidly generate full-length infectious cDNAs that afford genetic control over the genome. Full-length infectious cDNAs were isolated for TGEV, HCoV-229E, IBV and MHV strain A59 [17-21]. The approach described herein has been to isolate a panel of cDNAs spanning the entire coronavirus genome, which can be systematically and directionally assembled
10 into a genome-length cDNA by *in vitro* ligation [17, 18].

Patterned after the strategy devised for TGEV [18], the SARS genome was cloned by RT-PCR as six contiguous subclones linked by unique *Bgl* I restriction endonuclease sites. *Bgl* I is a class IIS restriction endonuclease that cleaves the symmetrical sequence GCCNNNN¹NGGC, but leaves 64 different asymmetrical
15 ends. Consequently, pairs of contiguous subclones encoded junctions that allow unidirectional assembly of intermediates into a full-length cDNA. Two *Bgl* I junctions were derived from sites encoded within the SARS-CoV genome at positions nt 4373 (A/B junction) and nt 12,065 (C/D junction) [8-10]. A third *Bgl* I site at position nt 1557 was removed and new *Bgl* I sites were inserted by the introduction of
20 silent mutations into the SARS-CoV sequence at positions nt 8700 (B/C junction), nt 18,916 (D/E junction) and at nt 24,040 (E/F junction). These mutations are shown in the Sequence Listing as SEQ ID NOs:10-14. SARS-CoV sequence toxicity was circumvented by disruption of toxic domains and the use of stable cloning vectors [17]. The resulting cDNAs include SARS A (nt 1-4436), SARS B (nt 4344-8712),
25 SARS C (nt 8695-12,070), SARS D (nt 12,055-18,924), SARS E (nt 18,907-24,051) and SARS F (nt 24,030-29,736) subclones. The SARS A subclone contains a T7 promoter and the SARS F subclone terminates in 21 Ts, allowing for *in vitro* transcription of capped, polyadenylated transcripts.

Numerous mutations were noted in each of the four to seven sibling subclones
30 encoding a given SARS cDNA. To rapidly assemble a consensus clone, the "No See'm" approach was used with another group of class IIS restriction endonucleases that cut at asymmetric sites and leave asymmetric ends. These enzymes cut strand specific and allow the seamless ligation of cDNAs with the loss of the restriction site

used to join two component clones [17]. As illustrated with the SARS F sibling clones, primer pairs were designed that contained terminal *Aar I* (CACCTGCNNNN[↓]NNNN) sites that flanked each of the various consensus portions of different sibling clones. In some instances (amplicons 3 and 2 in sibling clones 1 and 4, respectively), primers were also designed to repair specific mutations located near the ends of a given amplicon. The combination of high fidelity PCR, oligonucleotide primer repair and the seamless ligation of sequence fragments [17], rapidly generated Urbani consensus cDNAs for each of the SARS A, B, C, D, E and F subclones. Silent changes retained in the full length construct included an A to G change at nt position 6460, a T to C change at nt position 14,178, a T to C change at nt position 15,740, a C to T change at nt position 19,814, an A to G change at nt position 20,528 and a T to C change at nt position 20,555. These mutations are shown in the Sequence Listing as SEQ ID NOs:15-21.

15 Rescue of Molecularly Cloned SARS-CoV. To build full length SARS-CoV cDNAs, individual subclones were digested with the appropriate restriction enzymes, ligated together *in vitro* and used as template for *in vitro* transcription with the T7 RNA polymerase. Since N transcripts enhance RNA transfection efficiencies of TGEV and MHV [17, 22], and are essential for IBV transcript infectivity [20], SARS-CoV full-length transcripts were either electroporated into cells alone or mixed with SARS-CoV N transcripts. Within 48 hrs post transfection, SARS-CoV infected cells were detected by fluorescent antibody staining. Infectious virus (icSARS-CoV) titers approached 1.0×10^6 PFU/ml at 48 hrs postinfection in the mixed transcript transfected cultures. Recombinant viruses were also detected in cultures transfected with genome-length SARS transcripts alone, but titers were reduced. As described with MHV [17], SARS N transcripts may enhance infectivity of SARS full-length transcripts, but are not essential. The molecular cloned viruses were plaque purified in VeroE6 cells and produced similar sized plaques as wild type SARS Urbani.

30 icSARS CoV Marker Mutations. Rescued icSARS-CoV, but not wild type SARS-CoV should contain several *Bgl I* sites that were engineered as junctions between the SARS B/C, D/E and E/F subclones and lack the *Bgl I* site at nt position 1557. Intracellular RNA was isolated from infected cultures, RT-PCR amplified using

primer pairs flanking these various sites and subjected to restriction fragment length polymorphism (RFLP) analysis with *Bgl* I. Clearly, icSARS-CoV contained the marker mutations inserted within and between the component clones. To confirm these findings, selected amplicons were cloned and sequenced, demonstrating that the
5 icSARS-CoV originated from transcripts derived from the full-length cDNA construct.

Phenotype of Rescued icSARS-CoV. Cultures of cells were infected with an MOI of 5. In untreated cultures, intracellular RNA and virus titers were determined as
10 described herein. At 1 hr, cultures were treated with E64-d at a concentration of 500 µg/ml and virus titers determined by plaque assay in VeroE6 cells.

The recombinant icSARS CoV isolate replicated as efficiently as wild type Urbani, but less efficiently than the Canadian isolates, Tor-2 and Tor-7 SARS-CoV. These data demonstrate that the introduced alterations were not debilitating to virus
15 growth in culture as both replicated to titers of about 10^7 within ~24-48 hrs postinfection. To further characterize the transcription strategy of SARS-CoV, intracellular RNA was isolated from Urbani wild type and icSARS-CoV-infected cultures. Following RT-PCR amplification of leader containing amplicons, sequence analysis indicated that wild type and icSARS-CoV subgenomic transcripts originated
20 at identical CS sites, defined by the core sequence ACGAAC, as illustrated by leader-containing transcripts encoding X1, E, M, X3 and X4. SARS S and N encoding transcripts initiated subgenomic transcription at similar CS sites. This sequence represents a truncation of the AAACGAAC CS site that had been predicted by Rota et al., 2003 and is different from the group I, II and III coronavirus CS sequences,
25 CUAAAC (TGEV), UCTAAAC (MHV), and CUUAACAA (IBV), respectively. Although previous studies had suggested that the SARS E protein and ORF X3 might be expressed from polycistronic mRNA, these findings indicate that independent transcripts are initiated at the core CS sequence ACGAAC noted at nt positions 26,109 for E transcripts and 26,913 for ORF X3 transcripts, respectively.

30

In vitro inhibition of SARS-CoV Replication. Given the high virulence of SARS-CoV infection in humans, antiviral drugs will be required to reduce the scope and severity of disease. In MHV, the cysteine proteinase inhibitor E64-d blocks replicase polyprotein processing and thereby inhibits viral RNA synthesis and virus growth

[11]. To determine if icSARS-CoV was susceptible to the inhibitory effects of E64-d, growth analysis was performed in the presence and absence of 500 µg/ml of drug. In the absence of E64-d, wild type and icSARS-CoV grew to equivalent titers of $\sim 1.0 \times 10^7$ PFU/ml after 24-48 hrs postinfection. Treatment of cells with a single dose of
5 E64-d at 1 hr pi resulted in almost complete elimination of viral CPE and viral antigen expression and a significant ~ 3 -4 log reduction in virus yield for both wild type SARS-CoV and icSARS-CoV at 24 and 48 hrs postinfection.

Example 2. . Development of SARS virus single hit replicon vector vaccines.

10 **SARS Replicon Particle Assembly.**

Viral replicon particles are single hit vectors that are incapable of spreading beyond the site of initial infection and are novel vaccine candidates for human and animal diseases. The SARS single hit replicon particles will be produced in the helper cells as described herein. Specifically, the SARS E, M, S and/or N structural
15 proteins will be produced in helper cells from helper RNA or DNA, e.g., VEE VRPs, noncytotoxic Sindbis virus replicons, BAC or vaccinia vectors, CMV eukaryotic expression plasmids, etc., using standard protocols in order to provide SARS coronavirus structural proteins in trans for assembly of coronavirus replicon particles in helper cells. The SARS E, M, S and/or N coding sequences will be deleted from
20 the replicon RNA and one or more heterologous coding sequences will be inserted into the replicon RNA. The replicon RNA will be packaged into coronavirus particles in the helper cells. Populations of the particles produced in the helper cells as described herein can be tested for the ability to maintain only a single round of infection by passage on coronavirus-permissive cells.

25

Cell Preparation: VERO E6 Cells Expressing SARS E protein or M glycoprotein.

Sindbis noncytotoxic replicon vectors (pSinRep) induce persistent infections in VERO and BHK cells, and constitutively express resistance to puromycin and a
30 foreign gene of interest. these vectors have been used to constitutively express human CEA receptors in BHK cells, converting these cells to susceptible hosts for the MHV host range mutant V51. SARS E and M coding sequences will be inserted into pSinRep or CMV expression vectors, VERO E6 cells will be transfected and selected with puromycin (or G-418 for CMV vectors) for clones that stably express high

concentrations of selected SARS structural proteins. The SARS E protein and M glycoprotein will also be expressed from VEE VRPs, and inoculated into mice for the production of monospecific antisera against each of these proteins. VEE VRPs have been used to produce high titer antiserum against Norovirus antigens, as well as the TGEV M and N proteins. Using flow cytometry and polyspecific antisera directed against the SARS E protein and M glycoprotein, enrichment for cells expressing high or low levels of the desired protein will be carried out. As VERO E6 cells are susceptible hosts for SARS replication, these cells will allow for additional rounds of infection with SARS VRPs with subsequent packaging and release of progeny VRPs.

10

SARS Vector Replicon Design:

First, a determination will be carried out regarding whether any of the group specific ORFs (X1-X5) can be deleted and replaced with either luciferase or GFP. Specifically, the focus will be on ORFs X1, X4 and X5 because of their position in the genome and the possibility that they encode luxury functions that are not essential for replication *in vitro*. The overall goal is to identify a group specific ORF that can be deleted and replaced with an indicator gene that allows for easy visualization of replication and gene expression. Such mutants will also be of value for drug screening. Essential points in these experiments are to leave the CS and surrounding flanking sequences intact, so that foreign gene expression is maximized. A second issue is that foreign genes may encode noncanonical CS sites that are transcriptionally active. To circumvent this problem, noncanonical "TAAACGAAC" CS sites in GFP or luciferase will be altered at the 3rd codon to prevent spurious expression of cryptic subgenomic RNAs. Growth curves will be performed to determine if rescued viruses replicate at equivalent levels with wild type SARS coronavirus and cultures will be examined for GFP or luciferase expression. The most viable of the ORFX1-X3 constructs will be used for future studies.

SARS replicon genomes will be assembled by systematically deleting the E and/or M genes using the No See'm Strategy described in Yount et al. (2002). These constructs will be built within a backbone that encodes the luciferase gene as described above. In the case of M, the M ORF will be deleted and GFP or luciferase will be inserted, leaving the M CS site intact. In the latter two instances, this approach will allow for coordinated and equivalent levels of expression of upstream

genes, while inserting a heterologous foreign nucleic acid for easy quantitation of VRP titers.

SARS replicon constructs will be assembled as described, except that Not 1 sites will be encrypted at the 5' end of Clone A and 3' end of Clone F. Following assembly, the DNA will be restricted with Not 1 and inserted into BAC vectors. This allows for BAC propagation in bacteria and circumvents tedious reconstructions of SARS replicon constructs. The stability of these BAC vectors will be evaluated by serial passage and sequence analysis.

Stable VRP Single Hit Expression Vectors.

Successful development of stable single hit SARS replicon vectors will be demonstrated by standard approaches. To titer VRP stocks, quantitative methods have been developed that rely on serial dilution and counting cells expressing nucleic acid encoding GFP or viral and heterologous antigens by fluorescent antibody staining in a number of randomly chosen but defined (μm^2) fields. Titers are estimated by counting the number of fluorescent cells in a known area, statistically determining the mean and then adjusting for total area of the plate. Alternatively, viral VRP stocks can be quantified by endpoint PCR or quantitative PCR, potentially compromised by an unknown particle/PFU ratio. It is expected that the SARS M glycoprotein and E protein will be essential for assembly and release, based upon experience with TGEV. However, it has been suggested that SARS is more closely akin to the group II coronaviruses like MHV, so it is also possible that SARS E protein may be nonessential for packaging and release.

A number of VRP phenotypes will be analyzed. The SARS VRPs lacking E protein should be single hit vectors in VERO E6 cells, but should serially passage in VERO E6 cells expressing E in trans. Similarly, SARS VRPs lacking M glycoprotein should be packaged and released from VERO E6 cells expressing M, but not E.

SARS VRP protein expression will be determined by Western Blot assays, to determine if E or M excision alters expression levels of other SARS structural and nonstructural ORFs as compared with wild type. This will be accomplished with antiserum generated from the VEE VRPs inoculated into mice. GFP or luciferase

expression will be measured by fluorescence and Western Blot assays, using commercially available antibodies and screens. The ability of different packaging cell lines (e.g., alphavirus vectored, CMV vectored) to support the production of high titrated SARS VRPs will be compared. RNA recombination is always a concern with
5 a vectored packaging cell lines, so progeny VRPs will be isolated and passaged several fold in a packaging cell line and passaged onto control cells lacking the appropriate structural protein *in trans*.

SARS-CoV Recombinant Protein Assays.

10 Venezuelan equine encephalitis virus (VEE) is a member of the alphavirus genus of the family Togaviridae. The virus consists of an icosahedral nucleocapsid composed of 240 copies of the capsid protein (C) surrounded by an envelope containing spikes formed from two glycoproteins, E1 and E2. The VEE genome is a positive sense single stranded RNA of 11.5kb, which replicates through a minus
15 strand intermediate. A subgenomic 26S mRNA, transcribed from the 26S promoter resident internally on the minus strand, encodes the structural proteins and is synthesized at ~10x molar excess relative to genome. Four nonstructural replicase proteins (ns_{p1-4}) mediate all transcription steps, which occur in the cell cytoplasm, and virus budding is at the plasma membrane.

20 The VEE genome, when introduced into a cell, can be viewed as a highly efficient machine for the production of large amounts of its own structural proteins through the transcription of a subgenomic mRNA encoding these proteins. If a nucleic acid of interest is substituted for the structural protein genes, then the VEE
25 replicative machine expresses high levels of that gene product. In the VEE replicon vaccine vectors, an immunizing gene is substituted for the structural protein genes. Upon electroporation of replicon RNA into cells, the VEE replication machinery produces high levels of the subgenomic mRNA and vectored gene product. However, as the structural protein genes are not present in the replicon RNA, no new virus
30 particles are released. One can package the replicon into "replicon particles" by supplying the structural proteins *in trans* from helper RNAs. The replicase proteins encoded on the replicon RNA provide the machinery for replicating the helper RNAs, while the structural proteins encoded by the helpers encapsidate and envelope the replicon RNA. Only the replicon RNA is packaged into VEE replicon particles

(VRP), because only the replicon RNA contains the *cis*-acting packaging signal. When VRPs infect another cell, either in culture or *in vivo*, the replicon RNA synthesizes high levels of the gene product, but no new replicon particles are formed due the absence of the structural protein genes. Therefore, these vectors are not cell
5 to cell transmitted.

Alphavirus Vectored Expression of Recombinant SARS-CoV Proteins.

The SARS S, E, N, M, and the group specific ORFs were cloned into VEE and packaged into VRPs. Following infection with VRP-S and VRP-N, cultures were
10 radiolabeled with ^{35}S -Met from 12-16 hrs post infection, resulting in the expression of a SARS ~46kDa N protein and a ~177/205 kDa S glycoprotein. VRP-E and VRP-M also expressed appropriately sized products using these conditions. Various VRP-group specific ORFs have also been inoculated into mice and cells. These data suggest 1) VRP immunization induced significant antibodies to authentic S protein
15 expressed from three different SARS isolates or with the rescued molecularly cloned icSARS-CoV (Similar results have been obtained with VRP-E, VRP-M and VRP-N antiserum), 2) patient serum was reactive with the S protein expressed by the VRPs and by icSARS-CoV, and 3) SARS ORF3a is immunogenic and detected by convalescent patient serum. The SARS-S gene, designed to produce either
20 membrane-bound or secreted forms, is also available and antiserum against the group specific ORFs is being raised in mice. SARS-CoV PRNT₉₀ titers were ~1:905 with VRP-S vs. <1:80 with VRP-HA (flu HA).

VEE replicon particles (VRPs) expressing the SARS S protein have been
25 constructed and antigen derived from cells infected with these vectors was initially evaluated as a target for EIA assays. Vero cells were infected with VRP-SARS(S) at a MOI of 6.0 for 15 hours and the cells were lysed with 0.5% NP-40. The optimal antigen concentration was found to be a 1:300 dilution. Using this assay, the human convalescent serum was shown to have an endpoint (the last dilution with an O.D.
30 reading ≥ 0.200) anti-SARS virus IgG titer of 1:3200, while serum from two uninfected control individuals had titers of < 1:200. Sera from mice that received a primary inoculation of VRP-SARS(S) in the rear footpads, followed by a boost at week 5 post primary inoculation, were evaluated at two weeks post boost and ranged from 1:1600 to 1:6400 (ave.=3300, n=12), while control animals that received VRP

expressing the influenza virus A/PR/8 HA gene had titers of 1:100-1:200 (ave=150, n=2). Similar assays were developed for other SARS structural protein, providing a unique panel of reagents to measure immune responses following SARS-CoV infection in rodents.

5

To perform CTL assays and other immunologic experiments, the SARS S and N proteins were inserted into vaccinia virus vectors.

Example 3. Deletion of SARS Virus Group Specific ORFs.

10 The SARS virus genome encodes several group specific ORFs at the 3' end of the genome including ORFs 3a/b (X1, X2), 6 (X3), 7a/b (X4), 8a/b (X5) and 9b. By analogy with other coronaviruses, it is believed that one or more of these group specific ORFs encode luxury functions that do not specifically contribute to virus replication *in vitro* but disable virus pathogenesis *in vivo*. This invention includes the
15 systematic and combined deletion or knocking out of expression of these various ORFs and rescue of the molecularly cloned viruses containing these genetic lesions. All recombinant viruses are obtained following transfection in Vero cells similar to those certified for cultivation and production of human virus vaccines.

20 Protocols are carried out wherein the group specific nucleic acid sequences designated ORFs 3a/b, 6, 7a/b, 8 and 9a are deleted. Initially, each of the ORFs is systematically deleted, either by deletion of individual ORFs (ORF3a-X1, ORF6-X3, ORF7a, ORF7b, ORF8a, ORF8b), entire TRS cistrons (e.g., ORF3a/b; ORF7a/b-X4; ORF8a/b-X5), or by mutations that specifically ablate ATG start codons and
25 introduce premature stop codons in an overlapping gene (ORF3b-X2, ORF9b). For deletions, a particular gene and its corresponding CS site (when appropriate) is excised, and the flanking upstream and downstream ORFs seamlessly stitched together. For example, two amplicons are isolated using primer pairs that are designed to contain external BsaI sites that are lost but leave complementary four
30 nucleotide asymmetric sites that direct seamless ligation of the SARS CoV ORF 6 and ORF 8 CS sites, simultaneously deleting the entire ORF 7a/b sequence. The ATG start is knocked out and a premature stop is inserted into ORF3a (X1) and ORF6 (X3) because virus phenotypes are not confounded by changes in transcription.

SARS-CoV from civet cats and human patients early in the epidemic contained a 29 bp insertion in ORF8a/b that resulted in a single ORF 8 protein. As it has been suggested that this deletion may have enhanced SARS-CoV pathogenicity in humans and perhaps transmission, the Civet cat full length ORF8 by fusing ORF8a and 8b will be reconstructed by insertion of the 29bp sequence identified in this virus, with the expectation that the addition of a full-length civet cat ORF8 will attenuate pathogenesis.

In mRNA3 transcripts encoding ORF 3a, ORF 3b is encoded as an overlapping out of frame 124 amino acid ORF that cannot be deleted without removing a significant portion of ORF 3a. If both ORFs encode luxury functions *in vitro*, recombinant viruses lacking each ORF will be rescued separately. While deletion of ORF 3a is straightforward, ORF 3b also contains ten in frame ATG start codons, thus selective mutagenesis of ORF3b start codons will only N-terminally truncate ORF X3b (if internal ATGs translate efficiently). Consequently, premature ORF3b stop codons will be introduced into the sequence:

“²⁵⁷³⁵CAGTGTCACAGAT” to “CAGTGTGACAGAT.” This alteration introduces a stop codon that truncates ORF3b after 24 amino acids, but doesn't change the protein sequence of ORF3a. A global approach is to combine this termination codon with additional mutations that destroy the ORF3b ATG start codon at residues 1 and 2, but leave the ORF 3a amino acid sequence intact. Changes will be introduced into the SARS CoV F subclone, which will be re-sequenced and then reassembled into full-length cDNAs. A similar strategy will be used to knockout ORF9b in mRNA9, which also encodes the N protein (ORF9a). Following *in vitro* transcription, full-length transcripts will be mixed with N transcripts (to enhance infectivity), introduced into cells by electroporation. Rescued viruses will be quantified by plaque assay.

Deletion of SARS-CoV Group Specific Genes.

The SARS-CoV ORF3a (X1), ORF 6 (X3) and ORF 7a/b (X4) domains have been deleted and recombinant viruses have been isolated that replicated in Vero cells. Moreover, ORF7a/b has been replaced with luciferase under control of the 7a/b TRS and is expressed in icSARS-CoVΔX4 infected cells. Following transfection, leader containing transcripts were identified, and ORF3a/ORF6/ ORF 7a/b deletions were confirmed by RT-PCR and sequencing. Passage of progeny virions revealed

abundant viral protein expression in icSARS-CoV, icSARS-CoV Δ X3 and Δ X4-
infected cultures, although protein expression in icSARS-CoV Δ X1 infected cultures
was less robust. At this time it is not possible to determine if this reflected a lower
initial transfection efficiency or lower rates of virus replication. The SARS-CoV X1
5 and X3 ORFs encode interferon antagonist genes. It seems likely that virus growth
might be boosted in certain cell types by providing IFN antagonist genes in trans,
should the Δ X1 molecularly cloned variant be highly attenuated in replication. Based
on findings with other highly pathogenic viruses, the deletion of IFN antagonists
should attenuate virus replication and pathogenesis *in vitro*. More importantly, the
10 data demonstrate the feasibility of using 1) the SARS-CoV cDNA reverse genetics to
modify the SARS-CoV genome, 2) that several group specific genes of SARS-CoV
encode luxury functions for *in vitro* growth (ORF3a, ORF3b, ORF6 and ORF7a and
ORF7b) and 3) it can be determined if deletion of SARS-CoV IFN antagonist genes
and group specific genes attenuate pathogenesis *in vivo* in the mouse, ferret and
15 eventually primate model for SARS-CoV pathogenesis. Deletion of ORF3a/b (X1
and X2 protein) also results in the rescue of viable progeny viruses, supporting the
notion that deletion of multiple accessory (group specific) ORFs still allow for the
recovery of robust viruses. All deletion mutants tested replicate to titers in excess of
 10^7 PFU/ml in 32 hrs. We have also produced a SARS-CoV isolate expressing GFP
20 from the ORF7a/b location. Recombinant viruses encoding either the Luciferase or
GFP indicator molecules provide a rapid screen for identifying compounds that block
SARS-CoV replication and gene expression. Reduced expression of either luciferase
or GFP in the presence of drug allows for rapid identification of compounds with
antiviral activity.

25

SARS-CoV Minimal Genome Recombinants/Multiple Accessory Gene Knockouts.

In addition to deleting each of the group specific ORFs, the nonessential ORFs
can be deleted in combination. The goal is to produce a minimal SARS genome
30 lacking as many of the group specific ORFs as possible (SARS Δ 3a/b,6,7a/b,8a/b),
while retaining adequate levels of virus replication *in vitro*. In the case of MHV,
deletion of group specific ORFs significantly attenuated MHV pathogenesis in mice
and recombinants lacking combinations of group specific genes were generally more

attenuated than isolates lacking a single group specific ORF, but not always. No experiments were conducted to determine if mutant-infected animals were protected against wild type challenge.

5 All TGEV and MHV group specific ORFs were nonessential for *in vitro* replication and at least ORF3a (X1), ORF3a/3b (X1/X2), ORF6 (X3) and ORF7a/b (X4) are nonessential for SARS-CoV replication. Thus, most, if not all, of the SARS virus group specific ORFs are believed to be capable of being deleted, resulting in a minimal genome that should be attenuated *in vivo*. Following mutagenesis of the SARS F subclone, assembly of the cDNAs and electroporation of transcripts,
10 recombinants will be rescued from transfected cultures.

Other attenuating mutations.

Mutations can be inserted virtually anywhere in the SARS-CoV genome
15 including the replicase, the replicase ribosome frame shifting site, 5' and 3' transcriptional regulatory sequences, and alterations in the SARS-CoV structural genes as examples.

Characterization of Rescued Viruses.

20 Rescued viruses will be harvested between 24 to 36 hrs post transfection and plaque purified prior to isolating low passage stocks in Vero E6 cells. During production of the recombinant virus stocks, passage numbers will be kept to a minimum so that potential 2nd site compensatory changes that restore virus replication and fitness do not have time to evolve and severely complicate an accurate
25 interpretation of the effects of particular changes on SARS replication fitness.

Genotype Analysis.

Plaque purified molecularly cloned viruses will be inoculated into Vero E6 cells and intracellular RNA isolated using Trizol reagents. Using RT-PCR and
30 primer-pairs that flank the various group specific ORFs, the presence or absence of group specific ORFs will be determined in recombinant viruses by size analysis of PCR product and by sequence analysis of amplicons. The S gene through the 3' end of the genome will also be cloned and sequenced to identify potential 2nd site alterations that may have evolved in response to group specific gene deletion. As

the gene order has been restructured by deleting various group specific ORFs, it is possible that these rearrangements may restructure TRS networks and the function of individual CS sites involved in the synthesis of a particular subgenomic transcript (most likely a gene upstream or downstream of the deleted ORF). To determine if subgenomic RNA synthesis originated from the appropriate CS sites, leader
5 containing amplicons that flank the various group specific ORF deletions will be RT-PCR cloned and sequenced.

Phenotype Analysis.

10 There are no precise *in vitro* correlates to *in vivo* SARS pathogenesis, so a variety of phenotypic characteristics will be measured to provide a global view of rescued-virus fitness in cell culture. Virus growth will be evaluated in culture, as well as plaque morphology. Rescued molecularly cloned viruses will be analyzed for SARS protein expression by immunoprecipitation or Western blots using antiserum
15 from mice inoculated with alphavirus VRPs encoding the various SARS virus structural and group specific ORFs. By immunoblot, the expression of the structural and various group specific nonstructural proteins that are produced following gene deletion will be measured. Northern Blot analysis will be used to identify the viral mRNAs and determine if selected gene deletion(s) alter the molar ratio of the
20 upstream and downstream viral mRNAs. In selected instances, cultures will be radiolabeled with ³H-uridine and the labeling kinetics of viral mRNAs and replicative forms RNAs analyzed. These experiments will also determine 1) deletion effects on RNA expression patterns, and 2) deletion effects on relative molar ratios of mRNA. These experiments will also determine if full length and subgenomic length
25 replicative form RNAs are present in SARS virus infected cells, as shown with other group I and II coronaviruses.

Stability of Rescued Virus with Passage: *Compensatory Evolution.*

TGEV deletion and gene rearranged viruses have been shown to rapidly
30 evolve 2nd site compensatory changes that restore virus growth fitness *in vitro*. It is believed that the 2nd site changes will subtly alter coronavirus gene networks and protein-protein interactions to restore virus growth *in vitro*, yet enhance attenuation in animal models by subtly changing the affinity of these highly orchestrated interactions that influence replication in the human host. To test this hypothesis, the

most debilitated rescued viruses that have deletions in one or more group specific ORFs will be tested. Recombinant viruses will be inoculated onto Vero E6 cells and progeny viruses passaged into fresh cultures at 24 hrs intervals. After 15-20 passages, progeny virus will be plaque purified and compared to wild type virus by growth curves and gene expression patterns. The corresponding SARS E and F genome fragments will be cloned and sequenced. Consensus SARS E and F subclones will be assembled into the full length cDNA to identify the exact 2nd site mutations that restore replication fitness. In the case of multiple alterations, the mutation that confers the strongest fitness recovery phenotype will be tracked. Although replicase mutations may also restore growth, preliminary data suggests that most of the compensatory changes will cluster at the 3' end of the genome.

Rewiring the Coronavirus Genome. Mutation in the SARS Transcription Regulatory Sequence Attenuates Replication and Recombination. Live virus vaccine development provides an approach for identifying virulence alleles and pathogenic determinants, providing a template our understanding viral pathogenesis. Live viruses that lack several of the SARS-CoV group specific ORFs have been rescued, and are being tested for whether such viruses are attenuated.

The coronavirus TRS includes the highly conserved CS and flanking sequences, which regulate the efficiency of coronavirus transcription. It is believed that 1) mutations in the leader and body CS will attenuate SARS-CoV gene expression, and 2) SARS-CoV CS regulatory networks can be rewired, making these rescued viruses highly resistant to RNA recombination repair at the 3' end of the genome. The goal is to develop viruses that have significantly different TRS regulatory networks that upon recombination create incompatibility networks that disrupt expression of subgenomic mRNAs. These "rewired" SARS-CoV will be highly resistant to recombination repair from wild type viruses and other coronaviruses. These experiments will enhance the feasibility of safe SARS-CoV attenuated seed stocks for killed vaccines and serve as a model for engineering recombination resistant viruses.

Leader/body CS Compensatory Mutations.

Previous studies with arteriviruses and TGEV indicated that mutations in the leader CS globally suppress transcription of all subgenomic mRNAs, unless the

corresponding mutations are also duplicated into the body CS. Rewiring the Nidovirus transcription regulatory network provides a novel approach to selectively attenuate gene expression of certain genes while maintaining efficient expression of other genes. The current hypothesis is that the actual CS sequence is not so critical, the major factor being that CS sites must allow for communication via efficient base-pairing for discontinuous transcription of subgenomic RNAs. It is believed that double and triple compensatory mutations in the leader/body CS will allow for viable viruses with robust gene expression, but be highly resistant to recombination repair.

Selected mutations (CS mutations 1 and 2) will be inserted into the 5' leader CS and body CS of the N structural gene (Tables 1 and 2), in essence producing SARS-CoV single hit replicon RNAs as described herein. N CS sites are targeted initially, as N subgenomic transcripts are closest to the 3' end of the genome and expressed most abundantly, providing a reliable signal for detection. N transcript expression from single hit TGEV replicons has been detected under similar conditions. The CS mutational spectra were chosen as: 1) the sequence is unique in the SARS-CoV genome and 2) it differs from CS sites present in other group I-III coronaviruses. Cultures will be transfected with recombinant virus RNA genomes and subgenomic transcription will be measured by quantitative RT-PCR using primers in the leader sequence and the body sequence of several structural genes, including N and genomic RNA. It is expected that robust N transcript expression will be demonstrated, with little if any expression of other subgenomic mRNAs. It may prove necessary to test other potential leader/body CS sequences that effectively optimize subgenomic expression of N, but not the other SARS-CoV transcripts. This will be tested empirically should the initial mutations prove unsatisfactory for driving mRNA expression (as determined by the relative ratio of genome to mRNA expression).

Using the most robust CS sites identified in the initial experiment, the remainder of the SARS-CoV CS sites will be converted to the new consensus sequence. Recombinant viruses (csSARS-CoV) will be assembled and transcripts electroporated into cells. Such viruses will be viable in culture and should express normal ratios of mRNA, RF RNA and protein.

At 24-36 hrs post transfection, rescued viruses will be plaque purified and stocks grown in Vero E6 cells as previously described. Virus passage will be minimized to prevent the emergence of 2nd site compensatory changes that restore virus growth fitness in culture. If recombinant viruses grow inefficiently, virus will be passaged 15-20X and mutants with increased growth kinetics and gene expression patterns will be identified by comparison with wild type (e.g., growth curves, structural protein expression, and northern blots). Given that reversion to wild type sequence in the leader/body CS sites is unlikely because of the requirement for multiple mutations (~18-27 changes in total genome CS sites), revertants will likely contain compensatory changes that reside in replicase proteins that interact with SARS-CoV TRS sites or in the flanking TRS sites that regulate discontinuous transcription (less likely as several would be required). These will be identified by sequence analysis followed by reintroduction of specific mutations into the full length cDNA construct.

Genotype Analysis.

Plaque purified molecularly cloned viruses will be inoculated onto Vero E6 cells and intracellular RNA isolated using Trizol reagents. Using RT-PCR and primer-pairs that flank selected leader and body TRS mutations, amplicons will be sequenced to confirm that rescued viruses contain the expected alterations. Using RT-PCR, leader-containing amplicons representing each of the downstream transcripts that are synthesized during infection will also be cloned and sequenced. However, it is possible that altered CS mutants might initiate subgenomic transcripts from noncanonical sites. Any such aberrant leader-containing amplicons will be identified by sequencing. Depending upon the level of expression, the aberrant CS sequence in newly emerged TRS sites will be mutated to knock out indiscriminant subgenomic transcription.

Phenotype Analysis.

Virus growth will be evaluated in culture and by plaque morphology. Rescued molecularly cloned viruses will be analyzed for SARS protein expression by Western Blot using antiserum from mice inoculated with alphavirus replicon particles encoding the various SARS structural and selected group specific ORFs. The ratios of structural proteins that are expressed in the rescued viruses will be determined by

Western blot. Northern blot analysis will be used to identify the viral mRNAs and determine if selected TRS mutations alter the molar ratio of the upstream and downstream subgenomic viral mRNAs or the emergence of additional transcripts originating from newly recognized body CS sites. In selected instances, cultures will be radiolabeled with ^3H -uridine and the labeling kinetics of viral mRNAs and replicative form RNAs will be analyzed.

New CS sites will be demonstrated to be stable in the SARS-CoV genome and allow for efficient gene expression and virus growth. The stability of selected mutants will be determined by serial passage in Vero E6 cells with particular focus on: 1) stability of leader/body CS sites and the evolution of group specific gene expression, and 2) mechanisms of fitness recovery. Putative compensatory mutations that restore virus replication fitness will be reintroduced into the full-length construct to prove causality between particular alterations, growth recovery and enhanced gene expression.

RNA Recombination with wild type SARS-CoV.

Several approaches will be used to test whether "re-networked" SARS-CoV can recombine efficiently with wild type SARS-CoV. In one approach, select wild type CS sites will be introduced back into the SARS-CoV re-networked genome. For example, the M CS site will be altered back to "ACGAAC" and a determination will be made regarding whether viable recombinant viruses can be isolated. As the M glycoprotein is essential for growth, this is a strong selective screen for viability. It is anticipated that such viruses will grow poorly and require passage for selection of compensatory changes that reestablish growth. Such changes would likely evolve within the CS site, given only 1 or 2 mutations might be required to restore functionality of the body CS. In a second approach, a theoretical single crossover recombinant virus that contains the "mutated" leader CS will be coupled with all 3' end CS sites derived from the wild type virus. Reflecting what would happen if a recombination event occurred in the replicase of a "re-networked" virus and wild type virus, it will be determined if the engineered leader CS site will communicate and drive subgenomic transcripts from a wild type 3' end genome. It is anticipated that such viruses would be heavily impaired and that subgenomic transcription might occur from noncanonical sites. Subgenomic transcription will be measured by

quantitative RT-PCR using primer sets in the leader sequence and in various structural genes. Transfected cultures and supernatants will be passaged (15-20X) to allow for the emergence of revertants that will be analyzed as described herein. Reversion, if it occurs, would likely occur through the emergence of one or more mutations in the leader CS. In a third approach, as in the second approach, a similar experiment will be performed, but in this instance, the 3' end of the re-networked SARS-CoV genome will be replaced with the 3' end of MHV (S through N). In one construct, the 3'-most ~500 nucleotides of the SARS-CoV genome that might contain cis-acting sequences needed for replication will be maintained and in a second construct, the entire SARS-CoV N gene and CS site will be included. In essence, a potential double recombinant genome will be generated that might occur between another group II coronavirus and SARS-CoV. Such viruses are not anticipated to be viable because of communication problems between the SARS-CoV replicase and the leader/body CS sites and potential encapsidation sequence problems associated with an MHV N protein (construct 1). In the second construct, the N protein will be derived from SARS-CoV but it must communicate with the MHV M, E and S proteins to mediate assembly of infectious virus, which is not likely.

Other rewiring approaches to prevent recombination repair of live attenuated viruses:

Other approaches to produce recombination resistant viruses include: 1) repositioning the SARS-CoV encapsidation sequence to different locations in the genome, 2) rewiring the replicase protein cleavage sites to a different recognition sequence, 3) reorganizing the SARS-CoV gene order and 4) any other methods that establish genome incompatibilities following recombination with any other circulating human strain.

Example 4. SARS Virus Gene Order Rearrangement.

Because N gene rearrangements are well tolerated in the group I and II coronavirus genomes, in initial studies, the N gene position will be moved to new sites immediately downstream (SARS SNEM) and upstream of S (SARS NSEM). Second generation constructs will include rearrangement of ORF7 or 8, the N gene upstream of S (SARS 7/8NSEM6) and an E protein/M glycoprotein reposition upstream of S as well (SARS EMSN). The SARS S glycoprotein will also be

repositioned to the 3' proximal location (SARS EMNS). The putative IFN antagonist genes encoded in ORF3a and ORF6 will also be repositioned, potentially altering levels of gene expression and activity. Depending upon the outcome of these experiments, more radical rearrangements may be performed in which multiple genes are repositioned to multiple sites. Care will be taken to maintain tight genetic juxtaposition and the appropriate TRS control such that rearranged genes will use their normal CS site for expression of subgenomic mRNAs. After introducing these rearrangements into the SARS F subclone, sequence analysis will be used to identify the consensus cDNA used in the assembly of full length SARS cDNAs. Molecularly cloned viruses will be rescued as described. Any number of rearranged SARS-CoV genomes can be built using the molecular clone or any other method to alter the 3' end of the SARS-CoV genome. Gene order rearranged viruses should be significantly resistant to recombination repair.

15 **Phenotype and Genotype Analysis of Rescued Viruses.**

Rescued viruses will be isolated between 24-36 hrs post transfection, plaque purified and stocks grown in Vero E6 cells as previously described. Virus passage will be minimized to prevent the emergence of mutations that restore growth fitness in culture.

20

Genotype Analysis.

Plaque purified molecularly cloned viruses will be inoculated into Vero E6 cells and intracellular RNA isolated using Trizol reagents. Using RT-PCR and primer-pairs that flank the newly rearranged genes, the presence of the mutant gene order in rescued viruses will be demonstrated. The amplicons will be sequenced to confirm the expected gene rearrangements. As rearrangements may alter expression of flanking genes, leader-containing amplicons will be RT-PCR cloned and sequenced to determine if subgenomic RNA synthesis has originated from appropriate CS sites.

30 **Phenotype Analysis.**

Virus growth will be evaluated in culture and by plaque morphology. Rescued molecularly cloned viruses will be analyzed for SARS protein production by Western Blot using antiserum from mice inoculated with VRPs encoding the various SARS

virus structural proteins and group specific ORFs. By Western Blot or immunoprecipitation with ^{35}S -methionine labeled cell extracts, the expression of the structural and various group specific nonstructural proteins that are expressed following gene rearrangement will be measured. Northern Blot analysis will be used to identify the viral mRNAs and determine if selected gene rearrangements alter the molar ratio of the upstream and downstream viral mRNAs. In selected instances, cultures will be radiolabeled with ^3H -Uridine and the kinetics of viral mRNA and replicative forms (RF) RNA synthesis will be analyzed. These experiments will allow for the determination of 1) whether full length and subgenomic length RF RNAs are present in SARS-CoV infected cells, 2) effects of reorganization on RNA expression, and 3) reorganization effects on relative molar ratios of mRNA and RF RNA.

Stability and Recombination Repair.

Compensatory Evolution. Recombinants will be inoculated into Vero E6 cells and progeny viruses passaged into fresh cultures at 24 hrs postinfection. After 15-20 passages, growth curves and plaque size will be compared to wild type virus. Then, consensus SARS E and F subclones that contain mutations of interest will be reintroduced back into the full length cDNA to identify 2nd site mutations that restore replication fitness in the rearranged viruses.

RNA Recombination Repair: Gene order rearranged viruses are expected to be highly stable and several fold more resistant to RNA recombination repair by wild type viruses. Using SARS NSEM and SARS wild type as an example, it is noted that most recombination events originating from SARS NSEM to SARS wild type will result in an N gene deletion, a lethal event which reduces the recombination frequency by one-half. In contrast, recombination events originating from SARS wild type to SARS NSEM will predominantly lead to recombinant genomes containing two copies of N, which at least in the case of TGEV reduces replication fitness by about 1 log of titer. Only recombination events occurring within the pol genes of both viruses will reconstruct wild type virus, hardly a significant problem as it would only add to the wild type virus burden already present. Consequently, it is expected that gene order rearrangements will attenuate RNA recombination repair to give wild type genomes. In the absence of wild type virus, it is highly unlikely that RNA recombination can restore the gene order of SARS NSEM. This is because several recombination events

are necessary, including duplication of the N gene at the 3' end of the genome (a double recombination event), followed by deletion of N from the upstream position.

To test this hypothesis, two approaches will be used. In the first approach, cultures of cells will be coinfectd with selected gene order rearranged viruses (SARS SNEM) and SARS wild type virus containing a deletion in the S CS and N-terminal S protein sequence and a GFP indicator. This genome should replicate but result in noninfectious virus particles lacking S. Rescue of the genome can occur by recombination or by phenotypic mixing of S glycoprotein provided by SARS SNEM in trans. The basic approach is to transfect with SARS Δ S and then infect with SARS SNEM at a MOI of 2 and passage progeny 3X (at high MOI SARS Δ S should passage if S provided in trans). Using quantitative RT-PCR and primer pairs spanning the N/adjacent gene (SARS SNEM would be N/ORF3a; SARS wild type would be ORF8/N), virions will be harvested from supernatants at each passage, concentrated through gradients, and titered by plaque assay and quantitative RT-PCR using primer sets that detect SARS SNEM, SARS wild type and SARS SNEMN recombinant viruses. Green plaques (3X) can also be plaque-purified and the genotype of recombinant viruses characterized. In the second approach, a SARS 2N virus (the progeny of a wild type x SNEM recombination event) is constructed, which is expected to be replication impaired as compared to wild type.

The foregoing examples are illustrative of the present invention, and are not to be construed as limiting thereof. The invention is described by the following claims, with equivalents of the claims to be included therein.

All publications, patent applications, patents and other references cited herein are incorporated by reference in their entireties for the teachings relevant to the sentence and/or paragraph in which the reference is presented.

References

1. Tsang KW, Ho PL, Ooi GC, Yee WK, Wang T, Chan-Yeung M, Lam WK, Seto WH, Yam LY, Cheung TM, et al..(2003). N Engl J Med 348:1977-1985.

2. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF et al., (2003). *N Engl J Med* **348**:1986-1994.
3. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS et al., (2003) *Lancet* **361**: 1767-1772.
- 5 4. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, Draker R, Adachi D, Ayers M et al, (2003). *N Engl J Med.* **348**: 1995-2005.
5. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, et al, (2003) *Lancet* **361**: 1319-1325.
6. Ksiazek TG, Erdman D, Goldsmith C, Zaki SR, Peret T, Emery S, Tong S, Urgani C, Comer JA, Lim W et al (2003) *N Engl J Med* **348**: 1953-1966.
- 10 7. Drosten C, Gunter S., Preisner W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA et al. (2003) *N Engl J Med* **348**: 1967-1976.
8. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH et al. (2003) *Science* **300**:1394-1398.
- 15 9. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chang SY et al. (2003) *Science* **300**: 1399-1404.
- 20 10. Ruan YJ, Wei CL., Ee LA, Vega VB, Thoreau H, Yun ST, Chia JM, Ng P, Chiu KP, Lim L et al, (2003) *Lancet* **361**: 1779-1785.
11. Kim JC, Spence RA, Currier PF, Lu XT, Denison MR (1995). *Virology* **208**:1-8.
12. Kanjanahaluethai A, Jukneliene D and Baker, SC. (2003) *J Virol* **77**: 7376-7382.
- 25 13. Gorbalenya AE, Koonin EV and Lai MMC. (1991) *FEBS Lett* **288**: 201-205.
14. Lu, X.T., Sims AC, and Denison MR. (1998) *J Virol* **72**: 2265-71.
15. von Grotthuss M, Wyrwicz LS, and Rychlewski L. (2003). *Cell* **113**: 701-702.
16. Zeibuhr J, Snijder EJ, Gorbalenya AE. (2000) *J Gen Virol* **81**: 853-879.
- 30 17. Yount B, Denison MR, Weiss SR and Baric RS.(2002) *J Virol.***76**: 11065-11078.
18. Yount B, Curtis C, and Baric RS. (2000) *J. Virol.* **74**: 10600-10611.
19. Almazan F, Gonzalez JM, Penzes Z, Izeta A, Calvo E, Plana-Durin J, Enjuanes L. (2000) *Proc Natl Acad Sci U S A* **97**: 5516-5521.

20. Casais R, Thiel V, Siddell SG, Cavanagh D, Britton P. (2001) *J Virol* **75**:12359-12369.
21. Thiel V, Herold J, Schelle B and Siddell SG. (2001). *J Gen Virol* **82**: 1273-81.
22. Curtis KM, Yount B, and Baric RS. (2002) *J Virol* **76**:1422-1434.
- 5 23. Pensaert MB, de Bouck P. (1978) *Arch Virol* **58**: 243-247.
24. Pensaert M, Callebaut P, and Vergote J. (1986). *Vet Q* **8**: 257-261.
25. Duarte M, Tobler K, Bridgen A, Rasschaert D, Ackermann M, Laude H. *Virology* **198**: 486-476.
26. Baric RS, Yount B, Hensley L, Peel SA and Chen W. (1997) *J Virol* **71**:1946-
10 1955.
27. Baric RS, Sullivan E, Hensley L, Yount B and Chen W. (1999) *J Virol*. **73**:638-649.
28. Fischer F, Stegen CF, Koetzner CA and Masters PS. (1998) *J Virol* **71**: 7885-7894.
- 15 29. de Haan CA, Masters PS, Shen X, Weiss S, Rottier PJ. (2002) *Virology* **296**:177-189.
30. Sola I, Alanso S., Zuniga S, Balasch M, Plana-Duran J, Enjuanes L. (2002). *J Virol* **77**: 4357-4369.
31. Ortega J, Escors D, Laude H, Enjuanes L (2002). *J Virol* **76**: 11518-11529.
- 20 32. Enjuanes, L., van der Zeijst BAM (1995). In: *The Coronaviridae*; SG Siddell, eds, p. 337-376.
33. Ladman BS, Pope CR, Ziegler AF, Swieczkowski T, Callahan CJ, Davison S, Gelb J Jr. (2002). *Avian Dis* **46**: 938-44.
34. Saif, L.J. (1999). *Adv Vet Med* **41**: 429-46.
- 25 35. van Nieuwstadt AP, Zetstra T, Boonstra J.(1989) *Vet Res.* **125**: 58-60.
36. Crouch CF, Oliver S, Hearle DC, Buckley A, Chapman AJ, Francis MJ. (2000) *Vaccine* **19**:189-196.
37. Park, S, Sestak K, Hodgins DC, Shoup DI, Ward LA, Jackwood DJ and Saif LJ. (1998) *Am J Vet Res* **59**:1002-8.
- 30 38. Rottier, P.J. (1999) *Vet Microbiol* **69**:117-25.
39. Vennema H, de Groot R., Harbour DA, Dalderup M, Gruffydd-Jones T, Horzinek MC, Spaan WJ. (1997) *J Virol* **64**:1407-1409.
40. Wang X, Schnitzlein WN, Tripathy DN, Girshieck T, Khan MI. (2002) *Avian Dis*, **46**: 831-838.

41. Baron MD, Foster-Cuevas M, Baron J, Barrett T. (1997) J Gen Virol.
80:2031-2039.
42. Fouchier RAM, Kuiken T, Schutten M, van Amerongen G, van Doorman GJ,
van den Hoogen BG, Peris M, Lim W, Stohr K, Osterhaus MD. (2003) Nature
5 423: 240.
43. Komatsu K, Inazuki K, Hosoya J, Satoh S. (1986) Exp Neurol 91: 23-29.

Table 1. SARS Consensus Sequences

TRS SITE	WT SEQUENCE	CS MUTANT #1	CS MUTANT #2
Leader CS	TAAACGAAC	TAAACGgtC	TAAcCGgtC
S CS	TAAACGAAC	TAAACGgtC	TAAcCGgtC
ORF3a	TAAACGAAC	TAAACGgtC	TAAcCGgtC
E CS	AGTACGAAC	AGTACGgtC	AGTcCGgtC
M CS	TAAACGAAC	TAAACGgtC	TAAcCGgtC
ORF6 CS	ATCACGAAC	ATCACGgtC	ATCcCGgtC
ORF7 CS	AAAACGAAC	AAAACGgtC	AAAcCGgtC
ORF8 CS	TAAACGAAC	TAAACGgtC	TAAcCGgtC
N CS	TAAACGAAC	TAAACGgtC	TAAcCGgtC

Table 2. SARS Consensus Sequences

TRS SITE	WT SEQUENCE	CS MUTANT #1	CS MUTANT #2
Leader CS	TAAACGAAC	TAAACGgAt	TAAcCGgAt
S CS	TAAACGAAC	TAAACGgAt	TAAcCGgAt
ORF3a	TAAACGAAC	TAAACGgAt	TAAcCGgAt
E CS	AGTACGAAC	AGTACGgAt	AGTcCGgAt
M CS	TAAACGAAC	TAAACGgAt	TAAcCGgAt
ORF6 CS	ATCACGAAC	ATCACGgAt	ATCcCGgAt
ORF7 CS ~	AAAACGAAC	AAAACGgAt	AAAcCGgAt
ORF8 CS	TAAACGAAC	TAAACGgAt	TAAcCGgAt
N CS	TAAACGAAC	TAAACGgAt	TAAcCGgAt

* the functional CS is an ACGAAC

What is Claimed is:

1. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:
 - a) SEQ ID NO:1 or SEQ ID NO:3 or a fragment of at least 25 contiguous nucleotides of SEQ ID NO:1 or SEQ ID NO:3;
 - b) a nucleotide sequence that is functionally equivalent to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3 but comprises different codons encoding the same amino acid sequences;
 - c) a nucleotide sequence having at least 70% homology to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3;
 - d) a nucleotide sequence having at least 95% homology to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3;
 - e) a nucleotide sequence that hybridizes to the complement of SEQ ID NO:1 or SEQ ID NO:3 under high stringency conditions;
 - and f) a nucleotide sequence having complementarity to any of the nucleotide sequences of (a) – (e) above.
2. The nucleic acid of claim 1, further comprising a promoter.
3. The nucleic acid of claim 2, wherein the promoter is selected from the group consisting of a T7 promoter, SP6 promoter, T3 promoter and a CMV promoter.
4. A cDNA of a SARS coronavirus, wherein all or part of a nucleotide sequence is deleted or inactivated and wherein the nucleotide sequence is selected from the group consisting of a nucleotide sequence encoding ORF1, ORF2, ORF3a, ORF3b, ORF4, ORF5, ORF6, ORF7a/b, ORF8a/b, ORF9a, ORF9b, and any combination thereof.
5. A cDNA of a SARS coronavirus, comprising a mutation in a nucleotide sequence selected from the group consisting of a nucleotide sequence encoding ORF1, ORF2, ORF3a, ORF3b, ORF4, ORF5, ORF6, ORF7a/b, ORF8a/b, ORF9a, ORF9b, ORF 10, ORF 13, ORF 14, and any combination thereof, wherein the mutation results in a nonfunctional gene product.

6. A cDNA of a SARS coronavirus, wherein the order of nucleotide sequences encoding replicase, accessory ORFs and/or structural proteins S, E, M and N is rearranged in comparison to the order in wild type SARS coronavirus.

7. A cDNA of a SARS coronavirus, wherein one or more of the nucleotide sequences encoding replicase, accessory ORFS and/or structural proteins S, E, M and N is present two or more times.

8. The cDNA of claim 6, wherein the order of nucleotide sequences encoding structural proteins is S, E, M and N is selected from the group consisting of a) 5' S, N, E and M 3', b) 5' N, S, E and M 3', c) 5' E, M, S and N 3', and d) 5' E, M, N and S 3'.

9. The cDNA of claim 7, wherein the order of nucleotide sequences encoding structural proteins is 5' S, N, E, M, N 3'.

10. A cDNA of a SARS coronavirus, comprising an attenuating mutation in a consensus sequence selected from the group consisting of a leader consensus sequence, an S (ORF2) consensus sequence, an ORF3a consensus sequence, an E consensus sequence, an M consensus sequence, an ORF6 consensus sequence, an ORF7 consensus sequence, an ORF8 consensus sequence and an N consensus sequence.

11. The cDNA of claim 10, wherein the mutation is selected from the group consisting of "ACGAAC" to "ACCAAC" and "ACGAAC" to AGGAAG."

12. A cDNA of a SARS coronavirus comprising a 29 bp insertion in ORF8a/b.

13. A cDNA of a SARS coronavirus wherein all or part of a nucleotide sequence is deleted or inactivated and wherein the nucleotide sequence is selected from the group consisting of a nucleotide sequence encoding ORF1, ORF2, ORF3a, ORF3b ORF4, ORF5, ORF6, ORF7a/b, ORF8a/b, ORF9a, ORF9b, and any

combination thereof and furthermore, wherein the order of nucleotide sequences encoding replication, accessory ORFs and/or structural proteins S, E, M and N is rearranged in comparison to the order in wild type SARS coronavirus.

14. The cDNA of claim 13, further comprising an attenuating mutation in a consensus sequence selected from the group consisting of a leader consensus sequence, an S consensus sequence, an ORF3a consensus sequence, an E consensus sequence, an M consensus sequence, an ORF6 consensus sequence, an ORF7 consensus sequence, an ORF8 consensus sequence and an N consensus sequence.

15. A SARS coronavirus replicon RNA comprising a coronavirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA lacks a sequence encoding at least one coronavirus structural protein.

16. The replicon RNA of claim 15, further comprising a sequence encoding at least one coronavirus structural protein.

17. The replicon RNA of claim 15, further comprising a promoter,

18. An infectious, multiplication-defective, coronavirus particle, comprising a SARS coronavirus replicon RNA, wherein the replicon RNA comprises a coronavirus packaging signal and a heterologous RNA sequence, and wherein the replicon RNA lacks a sequence encoding at least one coronavirus structural protein.

19. The particle of claim 18, wherein the replicon RNA comprises a sequence encoding at least one coronavirus structural protein.

20. The particle of claim 18 or the replicon RNA of claim 15, wherein the replicon RNA comprises a sequence encoding a replicase protein.

21. The replicon RNA of claim 15 or 16 or the particle of claim 18, 19 or 20, wherein the coronavirus structural protein is produced from nucleic acid of a coronavirus selected from the group consisting of SARS coronavirus, human respiratory coronavirus, mouse hepatitis virus, porcine transmissible gastroenteritis

virus, porcine respiratory coronavirus, canine coronavirus, feline enteric coronavirus, feline infectious peritonitis virus, rabbit coronavirus, murine hepatitis virus, sialodacryoadenitis virus, porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, avian infectious bronchitis virus, and turkey coronavirus, or any combination thereof.

22. The replicon RNA of claim 15 or 16 or the particle of claim 18, 19 or 20, wherein the coronavirus structural protein is selected from the group consisting of S, E, M, N or combinations thereof.

23. A DNA encoding the RNA of claim 15 or 16.

24. A population of infectious, multiplication defective, coronavirus particles, wherein each particle comprises a SARS coronavirus replicon RNA, and wherein the replicon RNA comprises a coronavirus packaging signal and a heterologous RNA sequence, and wherein the replicon RNA lacks a sequence encoding at least one coronavirus structural protein, wherein the population contains no detectable replication-competent coronavirus particles as determined by passage on coronavirus permissive cells in culture.

25. The population of claim 24, wherein the replicon RNA comprises a sequence encoding at least one coronavirus structural protein.

26. The population of claim 24 or 25, wherein the coronavirus structural protein is produced from nucleic acid of a coronavirus selected from the group consisting of SARS coronavirus, human respiratory coronavirus, mouse hepatitis virus, porcine transmissible gastroenteritis virus, porcine respiratory coronavirus, canine coronavirus, feline enteric coronavirus, feline infectious peritonitis virus, rabbit coronavirus, murine hepatitis virus, sialodacryoadenitis virus, porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, avian infectious bronchitis virus, and turkey coronavirus, or any combination thereof.

27. The population of claim 24 or 25, wherein the coronavirus structural protein is selected from the group consisting of S, E, M, N or combinations thereof.

28. A composition comprising the population of any one of claims 24-27 or the particle of any one of claims 18, 19 or 20 in a pharmaceutically acceptable carrier.

29. A method of introducing a heterologous RNA into a subject, comprising administering to the subject an effective amount of the particle of any one of claims 18, 19 or 20 or the population of any one of claims 24-27 or the composition of claim 28..

30. A method of inducing an immune response in a subject, comprising administering to the subject an effective amount of the particle of any one of claims 18, 19, or 20 or the population of any one of claims 24-27 or the composition of claim 28.

31. A helper cell for producing an infectious, multiplication-defective, coronavirus particle, comprising:

(a) a SARS coronavirus replicon RNA comprising a coronavirus packaging signal and a heterologous RNA sequence, wherein said replicon RNA further lacks a sequence encoding at least one coronavirus structural protein; and

(b) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, said helper RNA lacking a coronavirus packaging signal;

wherein the combined expression of the replicon RNA and the helper RNA produces an infectious, multiplication-defective coronavirus particle.

32. The helper cell of claim 31, wherein the replicon RNA further comprises a sequence encoding at least one of the coronavirus structural proteins.

33. The helper cell of claim 31, wherein the helper RNA comprises at least one nucleic acid sequence encoding a coronavirus structural protein selected from the group consisting of E, M, N and S.

34. The helper cell of claim 31, wherein the helper RNA comprises a nucleic acid sequence encoding an E coronavirus structural protein.

35. The helper cell of claim 31, wherein the nucleic acid encoding the coronavirus structural protein is from a coronavirus selected from the group consisting of SARS coronavirus, human respiratory coronavirus, mouse hepatitis virus, porcine transmissible gastroenteritis virus, porcine respiratory coronavirus, canine coronavirus, feline enteric coronavirus, feline infectious peritonitis virus, rabbit coronavirus, murine hepatitis virus, sialodacryoadenitis virus, porcine hemagglutinating encephalomyelitis virus, bovine coronavirus, avian infectious bronchitis virus, and turkey coronavirus or any combination thereof.

36. The helper cell of claim 35, wherein the coronavirus is SARS coronavirus.

37. The helper cell of claim 31, wherein the replicon RNA contains at least one attenuating gene order rearrangement among the 3A, 3B, HP, S, E, M and N genes.

38. The helper cell of claim 31, wherein the helper RNA comprises a promoter.

39. The helper cell of claim 31, wherein the replicon RNA comprises a promoter.

40. The helper cell of claim 31, further comprising a heterologous DNA encoding the helper RNA.

41. The helper cell of claim 31, further comprising a heterologous DNA encoding the replicon RNA.

42. A method of making infectious, multiplication-defective, coronavirus particles, comprising:

a) providing the helper cell of claim 31; and

b) producing coronavirus particles in the helper cell.

43. The method of claim 42, wherein the helper cell is provided by electroporating a cell to introduce the replicon RNA.

44. The method of claim 42, wherein the helper cell is provided by electroporating a cell to introduce the helper RNA.

45. The method of claim 42, wherein the helper cell is provided by electroporating a cell to introduce the replicon RNA and the helper RNA.

46. Infectious coronavirus particles produced by the method of claim 42.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number
WO 2005/035712 A3

(51) International Patent Classification:
C12N 15/50 (2006.01) C12N 15/67 (2006.01)

(21) International Application Number:
PCT/US2004/023548

(22) International Filing Date: 21 July 2004 (21.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/488,942 21 July 2003 (21.07.2003) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL** [US/US]; 308 Bynum Hall, Campus Box 4105, Chapel Hill, North Carolina 27599-4105 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BARIC, Ralph S.** [US/US]; 2600 Northstream Court, Haw River, North Carolina 27258-9529 (US). **YOUNT, Boyd** [US/US]; 1002 Scotsburg Trail, Hillsborough, North Carolina 27278 (US). **CURTIS, Kristopher M.** [US/US]; 102 Water Land Court, Frederick, Maryland 21702 (US).

(74) Agent: **MYERS BIGEL SIBLEY & SAJOVEC, P.A.**; P.O. Box 37428, Raleigh, North Carolina 27627 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
19 April 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/035712 A3

(54) Title: METHODS AND COMPOSITIONS FOR INFECTIOUS CDNA OF SARS CORONAVIRUS

(57) Abstract: The present invention provides a cDNA of a severe acute respiratory syndrome (SARS) coronavirus, recombinant SARS coronavirus vectors, and SARS coronavirus replicon particles. Also provided are methods of making the compositions of this invention and methods of using the compositions as immunogens and/or vaccines and/or to express heterologous nucleic acids.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/23548

A. CLASSIFICATION OF SUBJECT MATTER

IPC: C12N 15/50(2006.01),15/67(2006.01)

USPC: 536/23.72;435/320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.72; 435/320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARRA et al. The Genome Sequence of the SARS-Associated Coronavirus. Science. 30 May 2003. Vol. 30, pages 1399-1404, see entire document.	1
X	ROTA et al. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. Science. 30 May 2003. Vol. 300, pages 1394-1399, see entire document.	1
X	XU et al. Small envelope protein E of SARS: cloning, expression, purification, CD determination, and bioinformatics analysis. Acta Pharmacologica Sinica. June 2003. Vol. 24, no. 6, pages 505-511, see page 506.	1-3

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 September 2006 (22.09.2006)

Date of mailing of the international search report

18 OCT 2006

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Mary E. Mosher, Ph.D.

Telephone No. 571-272-1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/23548

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-3

- Remark on Protest
- | | |
|--------------------------|---|
| <input type="checkbox"/> | The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. |
| <input type="checkbox"/> | The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. |
| <input type="checkbox"/> | No protest accompanied the payment of additional search fees. |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/23548

BOX III. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group 1, claim(s) 1-3, drawn to nucleic acid comprising at least 25 consecutive nucleotides of SEQ 1 or 3, or related to SEQ 1 or 3 by variations recited in claims.

Group 2, claim(s) 4, 5, 13, 14, drawn to cDNA encoding mutated SARS genome with defective gene.

Group 3, claim(s) 6, 8, 13, 14, drawn to cDNA encoding a rearranged SARS genome.

Group 4, claim(s) 7, 9, drawn to cDNA encoding a gene-duplicated SARS genome.

Group 5, claim(s) 10, 11, 14, drawn to cDNA encoding attenuated SARS genome; see also species election for this group.

Group 6, claim(s) 12, drawn to cDNA encoding SARS with 29 bp insertion in ORF 8a/b.

Group 7, claim(s) 15-46, drawn to SARS replicon vector with heterologous nucleic acid.

Group 5 contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

- A. leader
- B. S (ORF2)
- C. ORF3a
- D. E
- E. M
- F. ORF6
- G. ORF7
- H. ORF8
- I. N

The claims are deemed to correspond to the species listed above in the following manner: Claims 10 and 14 are Markush claims which recite each of the above species.

The following claim(s) are generic: 11.

The inventions listed as Groups 1-7 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/23548

PCT Rule 13.2 states that the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

In this case, group 1 lacks a special technical feature, being anticipated by MARRA et al, The Genome Sequence of the SARS-Associated Coronavirus, Science, 30 May 2003, vol. 300, pages 1399-1404, see for example Table 2, line 1. MARRA discloses a nucleic acid sequence comprising at least 25 contiguous nucleotides of SEQ ID NO:1. Therefore no special technical feature unites the claimed inventions.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:
For Markush claims, unity of invention shall be considered to be met when the alternatives have a common structure or belong to a recognized class of chemical compounds (i.e. there is an expectation from the knowledge in the art that members of the class will behave in the same way in the context of the claimed invention. In other words, each member could be substituted one for the other, with the expectation that the same intended result would be achieved.). In this case, the different genes for locating attenuating mutations have no common structure, and none can be substituted for the other with the same result. Mutations in different subunits would be expected in the art to lead to qualitative and quantitative differences in attenuation, for example some would lead to decreased replication, some would lead to altered tropism, some would lead to altered inflammatory response, etc. Therefore the species do not all belong to a recognized class of chemical compounds for purposes of determining unity of invention.

Continuation of B. FIELDS SEARCHED Item 3:

EAST USpat Pgpud EPO JPO Derwent, Dialog 155, 73, 357; GenEmbl. Search terms: SEQ IDs 1, 3; SARS, sequenc? subunit, express?, py=2003.